Analysis of prescription pattern and adverse drug reactions of drugs used in Urinary Tract Infection in reproductive age group (15-44 years) women in a Tertiary Care Hospital in Central India: An observational retrospective study

Gayatri Patil; Sushil Varma

doi:10.12688/f1000research.149264.3

Home Browse Analysis of prescription pattern and adverse drug reactions of drugs...

ALL Metrics

Views

Downloads

Get PDF

Get XML

Export

▬

✚

Study Protocol

Revised

Analysis of prescription pattern and adverse drug reactions of drugs used in Urinary Tract Infection in reproductive age group (15-44 years) women in a Tertiary Care Hospital in Central India: An observational retrospective study

[version 3; peer review: 1 approved, 2 not approved]

Gayatri Patil ¹, Sushil Varma¹

PUBLISHED 05 Aug 2025

Author details Author details

¹ Pharmacology, Datta Meghe Institute of Higher Education and Research, Wardha, Maharashtra, 442001, India

Gayatri Patil
Roles: Writing – Original Draft Preparation, Writing – Review & Editing

Sushil Varma
Roles: Validation, Visualization, Writing – Original Draft Preparation

OPEN PEER REVIEW

REVIEWER STATUS

Abstract

Background

Urinary tract infection (UTI) is a frequent bacterial infection among women of reproductive age. Inappropriate and irrational prescribing of antibiotics—such as the use of unapproved fixed-dose combinations or empirical broad-spectrum therapy—has contributed to growing antimicrobial resistance. Adverse drug reactions (ADRs) further complicate treatment outcomes, yet remain underreported, especially in routine outpatient practice. Therefore, an assessment of current prescribing patterns and ADRs is essential to promote rational drug use.

Objectives

1.
To assess the prescribing patterns of antimicrobial and supportive drugs used for UTIs in women aged 15–44 years.
2.
To analyze the incidence, type, and severity of ADRs recorded during UTI treatment.
3.
To evaluate the use of fixed-dose combinations (FDCs) and combination antimicrobial therapy.
4.
To assess the extent of adherence to standard treatment guidelines.

Methods

This is a retrospective observational study based on outpatient department (OPD) prescriptions for women aged 15–44 years diagnosed with community-acquired, uncomplicated UTIs at a tertiary care hospital in Central India. Data from 139 prescription records will be retrieved from the medical record section and analyzed. Prescribing indicators, documented ADRs, and use of FDCs will be assessed against national guidelines using descriptive statistics, chi-square tests, and logistic regression analysis.

Keywords

Pattern, Prescription, urinary tract infection, adverse drug reaction, reproductive.

Corresponding author: Gayatri Patil

Competing interests: No competing interests were disclosed.

Grant information: The author(s) declared that no grants were involved in supporting this work.

Copyright: © 2025 Patil G and Varma S. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite: Patil G and Varma S. Analysis of prescription pattern and adverse drug reactions of drugs used in Urinary Tract Infection in reproductive age group (15-44 years) women in a Tertiary Care Hospital in Central India: An observational retrospective study [version 3; peer review: 1 approved, 2 not approved]. F1000Research 2025, 13:417 (https://doi.org/10.12688/f1000research.149264.3) First published: 29 Apr 2024, 13:417 (https://doi.org/10.12688/f1000research.149264.1) Latest published: 12 Sep 2025, 13:417 (https://doi.org/10.12688/f1000research.149264.5)

Revised Amendments from Version 2

In response to reviewer comments, several key changes were made to strengthen the scientific clarity and methodological rigor of the study. The sample size was recalculated using a 10% prevalence of adverse drug reactions (ADRs) rather than urinary tract infection prevalence, resulting in a final sample size of 139 patients. The study design was revised to a purely retrospective observational format, and all references to telephonic follow-up were removed. Inclusion criteria were restricted to female patients aged 15–44 years with community-acquired, uncomplicated UTIs seen in the outpatient department. The study objectives were rewritten for clarity, especially regarding ADR analysis and fixed-dose combination (FDC) evaluation. The statistical analysis section was expanded to include descriptive statistics, chi-square tests, and logistic regression using SPSS version 27, along with an explanation for handling missing data. The introduction was rewritten to include Central Indian antimicrobial resistance data and to better contextualize the study. The discussion was updated with a critical reflection on irrational prescribing, underreporting of ADRs, and study limitations. Operational definitions were added to the data collection table for clarity and replicability. The ethics section was updated to reflect that the study received institutional approval (DMIHER IEC/2024/159), with a waiver of consent for retrospective data use and administrative permission from hospital authorities.

See the authors' detailed response to the review by Niels Frimodt-Møller
See the authors' detailed response to the review by Vineetha Menon
See the authors' detailed response to the review by Sandip Mukhopadhyay
See the authors' detailed response to the review by Abayeneh Girma

Introduction

Urinary tract infection (UTI) is the most prevalent bacterial infection among women of reproductive age (15–44 years) because of their anatomical and physiological properties like shorter urethra, sexual activity, contraceptive use, and delayed micturition.¹^,²

UTIs are symptomatically differentiated into uncomplicated or complicated, and primary or recurrent, the most common uropathogen being Escherichia coli followed by Klebsiella, Staphylococcus, Streptococcus, and Pseudomonas species.³

A Karnataka, India, study conducted by Mahadevamma and Sarala (2011) revealed ciprofloxacin (23.8%), norfloxacin (14.3%), and ceftriaxone (13.3%) to be frequently prescribed in patients with UTI.⁴ Likewise, Chiang et al. (2019) indicated that fluoroquinolones (36.4%), nitrofurantoin (31.8%), and trimethoprim-sulfamethoxazole (26.3%) were the most frequently prescribed drugs for UTIs among women in a US-based review of 44.9 million prescriptions.⁵

Antibiotic resistance increases, especially to fluoroquinolones and third-generation cephalosporins, in Indian environments,⁶^,⁷ leading to a change to nitrofurantoin and sulfonamides as first-line therapy.

Although ADRs are an important concern in antimicrobial treatment, they remain underreported in retrospective hospital records, particularly in resource-poor environments. Nitrofurantoin is known to cause gastrointestinal disturbance, pulmonary toxicity, and liver damage.⁸ Sulfonamides are responsible for hypersensitivity reactions, hepatotoxicity, Stevens–Johnson syndrome, and hematologic toxicity.⁹

In spite of the availability of guidelines like the National List of Essential Medicines (NLEM 2022) and WHO procedures, irrational prescribing continues in the form of long-term use of broad-spectrum antibiotics and irrational fixed-dose combinations (FDCs).¹⁰

There is an obvious lack of Indian data on prescribing patterns and ADRs in reproductive-age women specifically.

Protocol

Nowadays, it is necessary to evaluate prescriptions due to the rapid changes in the prescriptions of diseases.

To analyze the irrational and inappropriate use of drugs this study is necessary.

For the improvement of patient compliance and to find out what type of adverse reactions are seen in reproductive age group female (15-44yrs) UTI patients due to prescribed drugs.

Aim

To analyze the prescription pattern and adverse drug reactions of drugs used in urinary tract infections of reproductive age group (15-44).

Objectives

Primary objectives

1. To assess the prescribing pattern of antibiotics and supportive drugs used in the treatment of community-acquired urinary tract infections (UTIs) in reproductive-age women (15–44 years).
2. To analyze the incidence, type, and documented severity of adverse drug reactions (ADRs) associated with these prescriptions as recorded in hospital OPD case sheets.

Secondary objectives

1. To evaluate the use of fixed-dose combinations (FDCs) and combination antimicrobial therapy for UTI treatment in this population.
2. To assess the alignment of prescribed drugs with standard treatment guidelines (e.g., WHO, NLEM 2022).

Methods

Statistical analysis

Data will be entered and analyzed using SPSS version 27.0. Descriptive statistics will be used to summarize baseline characteristics such as age, drug type, and comorbidities (mean ± SD or frequencies as appropriate).

Chi-square test will be used to examine associations between drug class and adverse drug reactions.

If the sample permits, binary logistic regression analysis will be performed to identify predictors of ADRs (e.g., age, pregnancy status, polypharmacy, comorbidity).

Missing data will be excluded from inferential analysis, and the extent of missingness will be reported.

A p-value < 0.05 will be considered statistically significant.

Inclusion criteria

The study will include prescription records of female patients aged 15–44 years attending the outpatient department (OPD) with a diagnosis of uncomplicated, community-acquired urinary tract infection (UTI).

Exclusion criteria

• Patients admitted to inpatient wards or ICU
• Cases of complicated or hospital-acquired UTI
• Incomplete or illegible case files

Study setting

This retrospective study will be conducted in the Department of Pharmacology at a Rural Tertiary Care Teaching Hospital in Central India, using prescription records retrieved from the hospital’s Medical Record Section.

Sample size estimation

Since the primary outcome of interest includes the analysis of adverse drug reactions (ADRs), the sample size is estimated based on the expected prevalence of ADRs in UTI drug prescriptions.

Using the Daniel formula:

n = Z^{2} \times P (1 - P) / d^{2} n = Z^{2} \times P (1 - P) / d^{2} n = Z^{2} \times P (1 - P) / d^{2}

Where:

• Z = 1.96 for 95% confidence
• P = 0.10 (assumed 10% prevalence of ADRs based on prior studies e.g., Fatima et al., 2015)
• d = 0.05d = 0.05 (desired precision = 5%)

$n = {(1.96)}^{2} \times 0.10 \times (1 - 0.10) / {(0.05)}^{2} = 138.3 \approx 139 patients$

Final sample size: 139 prescription records

Study design

This is a retrospective observational study using OPD records of women with UTI in the reproductive age group.

No patient contact or follow-up will be conducted.

No data will be taken from inpatients, ICU, or hospital-acquired infections.

Statistical methods

• Descriptive statistics: Frequencies, means, and standard deviations
• Chi-square test: To assess associations between drug classes and ADRs
• Logistic regression: To evaluate predictors of ADR occurrence (e.g., age, comorbidity)
• Handling of missing data: Records with missing critical variables will be excluded from analysis

Software used

All statistical analyses will be performed using SPSS Version 27.0 (IBM Inc., USA).

Data collection and procedure

We will collect recorded files of patients of reproductive age group female (15-44yrs) UTI patients from the medical record section. And Analyze prescriptions and adverse drug reactions of patients. Table 1 details the parameters included in the study.

Table 1. Parameters and operational definitions used in data collection.

Parameter	Operational definition
Age/Sex	Age in completed years; sex as recorded (female only included)
MRD No. /OPD No.	Unique identifiers from the hospital medical records
Diagnosis	Diagnosis of UTI recorded by treating physician, with or without supportive lab tests
Drugs Used	All antimicrobial and supportive drugs prescribed
Dose & Duration	As per prescription record (in mg/day and number of days)
Irrational Prescription	Prescriptions not adhering to NLEM 2022 or WHO treatment guidelines, including wrong drug choice, dose, duration, or unjustified combinations
Combination Therapy	Use of two or more antimicrobials prescribed for the same UTI episode
Fixed Drug Combinations	Pharmaceutical formulations with ≥2 active ingredients, e.g., Co-trimoxazole, Amoxicillin-Clavulanate; non-standard combinations (e.g., Nitrofurantoin + B6) excluded
Adverse Drug Reactions	Any documented undesirable event temporally related to a drug; classified as per hospital record using WHO-UMC system where available
Comorbidities	Presence of any chronic illness (e.g., diabetes, hypertension) recorded in the medical record
Pregnancy Status	As per documented clinical status during treatment
Recurrent Infections	≥2 documented UTI episodes within 6 months or ≥3 in a year
Duration of Illness	Duration between onset of symptoms and resolution as noted in case file

Dissemination

The results of this study may contribute to future systematic reviews or meta-analyses focused on prescribing patterns and adverse drug reactions in urinary tract infections.

Study status

The study is yet to be started.

Discussion

Today irrational and in appropriate use of drugs is a serious issue. Irrational drug use can lead to adverse effects such as drug resistance and drug side effects.¹¹^,¹² Nitrofurantoin, Trimethoprim-Sulfamethoxazole, and Fluoroquinolones are the drugs most frequently used to treat UTI.¹³ In this study we will examine the prescriptions of the drugs that will be prescribed for UTI.

This research will close that gap by assessing actual prescribing practice and pharmacovigilance in outpatient UTI care. This research is anticipated to underscore irrational prescribing and under-reporting of ADRs in the care of UTIs, which lead to antibiotic resistance and suboptimal patient outcomes.⁶^,⁷

The earlier research has reported poor compliance with guidelines and excessive use of combination therapy in Indian practice.⁴^,¹⁰ Lack of systematic monitoring of ADR can further hamper rational use of drugs, particularly among rural patients who have limited diagnostic facility access.⁸^,⁹

By analyzing prescription audit and ADR patterns, this paper will help support local antimicrobial stewardship and inform future policy.

For the improvement of patient compliance, it is very important to analyze prescription patterns and adverse drug reactions (ADRs). The benefits of our research will be patient care improvement and risk assessment and lesser events of adverse drug events associated with the prescribed drugs. Also, we will be analyzing the rationality of prescribing FDC and combination therapy. As well as their overall impact on the outcome of treatment.

This analysis is for the use of evidence-based medicine in tertiary care centers, to fulfill the drug information needs of the physician and also for improvement in the quality of healthcare by giving feedback to prescribers. This is an observational, retrospective study that will aim at the analysis of drug prescription patterns and adverse drug reactions due to drug prescription in urinary tract infections at tertiary health care centers.

Ethical considerations

The study was approved by the Institutional Ethics Committee of Datta Meghe Institute of Higher Education and Research (Deemed to be University), with reference number DMIHER (DU)/IEC/2024/159.

As this is a retrospective observational study received an Ethics Committee waiver of informed consent. Institutional permission was also obtained from the Chief Medical Superintendent (CMS) and the Medical Records Section for access to anonymized historical outpatient prescription data.

Data availability

No data are associated with this article at this stage. Data will be made available upon completion of the study, subject to institutional approval and journal policy.

Acknowledgements

AVBRH HOSPITAL, HMIS.

References

1. Medina M, Castillo-Pino E:An introduction to the epidemiology and burden of urinary tract infections. Ther Adv Urol. 2019; 11: 1756287219832172. PubMed Abstract | Publisher Full Text | Free Full Text
2. Foxman B:Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med. 2002; 113(Suppl 1A): S5–S13. Publisher Full Text
3. Flores-Mireles AL, Walker JN, Caparon M, et al.:Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol. 2015; 13(5): 269–284. PubMed Abstract | Publisher Full Text | Free Full Text
4. Mahadevamma L, Sarala N:Study of prescribing patterns of antimicrobial agents in urinary tract infection. Int J Pharm Bio Sci. 2011; 1(3): 1–5.
5. Chiang G, Wang H, et al.:Trends in antibiotic prescribing for urinary tract infections in women, 2000–2016. JAMA. 2019; 322(9): 890–891. Publisher Full Text
6. Kothari A, Sagar V:Antibiotic resistance in pathogens causing community-acquired urinary tract infections in India: a multicenter study. J Infect Dev Ctries. 2008; 2(5): 354–358. PubMed Abstract | Publisher Full Text
7. Taneja N, Rao P, Arora J, et al.:Occurrence of ESBL and AmpC β-lactamases and susceptibility to newer antimicrobial agents in complicated UTI. Indian J Med Res. 2008; 127(1): 85–88. PubMed Abstract
8. Huttner A, Kowalczyk A, Turjeman A, et al.:Safety of nitrofurantoin in renal impairment: a systematic review. Clin Microbiol Infect. 2015; 21(12): 1219–1228. Publisher Full Text
9. Roujeau JC, Kelly JP, Naldi L, et al.:Medication use and the risk of Stevens–Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995; 333(24): 1600–1608. Publisher Full Text
10. Government of India. National List of Essential Medicines (NLEM) 2022. Ministry of Health and Family Welfare. https://main.mohfw.gov.in/basicpage/national-list-essential-medicines-nlem-india
11. Melku L, Wubetu M, Dessie B:Irrational drug use and its associated factors at Debre Markos Referral Hospital’s outpatient pharmacy in East Gojjam, Northwest Ethiopia. SAGE Open Med.2021; 9: 205031212110251. Publisher Full Text
12. Ojo MA, Igwilo CI, Emedoh T:Prescribing patterns and perceptions of health care professionals about rational drug use in a specialist hospital clinic. J Public Health Afr. 2014; 5(2): 358. Publisher Full Text
13. Nicolle LE:Uncomplicated urinary tract infection in adults including uncomplicated pyelonephritis. Urol Clin North Am. 2008; 35(1): 1–12. Publisher Full Text

Comments on this article Comments (0)

Version 5

VERSION 5 PUBLISHED 29 Apr 2024

Author details Author details

¹ Pharmacology, Datta Meghe Institute of Higher Education and Research, Wardha, Maharashtra, 442001, India

Gayatri Patil
Roles: Writing – Original Draft Preparation, Writing – Review & Editing

Sushil Varma
Roles: Validation, Visualization, Writing – Original Draft Preparation

Competing interests

No competing interests were disclosed.

Grant information

The author(s) declared that no grants were involved in supporting this work.

Article Versions (5)

version 5

Revised

Published: 12 Sep 2025, 13:417

https://doi.org/10.12688/f1000research.149264.5

version 4

Revised

Published: 01 Sep 2025, 13:417

https://doi.org/10.12688/f1000research.149264.4

version 3

Revised

Published: 05 Aug 2025, 13:417

https://doi.org/10.12688/f1000research.149264.3

version 2

Revised

Published: 11 Feb 2025, 13:417

https://doi.org/10.12688/f1000research.149264.2

version 1

Published: 29 Apr 2024, 13:417

https://doi.org/10.12688/f1000research.149264.1

© 2025 Patil G and Varma S. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download

Export To

metrics

	Views	Downloads
F1000Research	-	-
PubMed Central Data from PMC are received and updated monthly.	-	-

Citations

SEE MORE DETAILS

CITE

how to cite this article

Patil G and Varma S. Analysis of prescription pattern and adverse drug reactions of drugs used in Urinary Tract Infection in reproductive age group (15-44 years) women in a Tertiary Care Hospital in Central India: An observational retrospective study [version 3; peer review: 1 approved, 2 not approved]. F1000Research 2025, 13:417 (https://doi.org/10.12688/f1000research.149264.3)

NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article.

track

receive updates on this article

Track an article to receive email alerts on any updates to this article.

Open Peer Review

Current Reviewer Status: ?

Key to Reviewer Statuses VIEW HIDE

ApprovedThe paper is scientifically sound in its current form and only minor, if any, improvements are suggested

Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.

Not approvedFundamental flaws in the paper seriously undermine the findings and conclusions

Version 3

VERSION 3

PUBLISHED 05 Aug 2025

Revised

Views

Reviewer Report 26 Aug 2025

Abayeneh Girma, Mekdela Amba University, Tulu Awlya, South Wollo Zone, Ethiopia

Not Approved

https://doi.org/10.5256/f1000research.185974.r402772

General comments
The manuscript addresses an important topic—prescription patterns and adverse drug reactions (ADRs) in urinary tract infections (UTIs) among reproductive-age women in Central India. However, despite revisions, significant methodological and conceptual flaws persist, compromising the study's scientific rigor, reproducibility, and potential impact. The study design, sample size justification, and clarity of objectives remain inadequate, as highlighted by previous reviewers. Below are the specific concerns that warrant rejection.

1. Study design and methodology:
(i) Retrospective vs. prospective contradictions: The authors claim a retrospective design but propose telephonic follow-ups for ADR data, introducing a prospective element. This hybrid approach lacks justification and risks bias (e.g., recall bias, non-response bias).
(ii) Data source clarity: The manuscript does not clearly specify whether UTIs are community-acquired or hospital-acquired, nor does it define diagnostic criteria (e.g., symptoms, culture results). This omission limits the interpretability of prescription patterns.
(iii) ADR collection: Relying on hospital records for ADRs is problematic due to underreporting. The plan to contact patients by phone is not standardized or ethically clarified (e.g., consent process).

2. Sample size and statistical power: The revised sample size calculation (n=139) is based on an assumed 10% prevalence of ADRs, which is an improvement. However, the justification remains weak, and the sample size may still be insufficient for robust conclusions, especially for secondary outcomes like combination therapy analysis. Again, the study lacks power calculations for subgroup analyses (e.g., by drug class, age, or comorbidity), which are critical for meaningful inferences.

3. Objectives and scope: The primary objectives are overly broad. For example, "analyzing adverse reactions" lacks specificity (e.g., which ADRs, severity grading). Additionally, the secondary objective to analyze fixed-dose combinations (FDCs) is commendable but poorly operationalized. Examples like "Nitrofurantoin + Vitamin B6" are questionable, as Vitamin B6 is not a standard UTI treatment.

4. Ethical and practical issues: While ethical approval is mentioned, the waiver for patient consent in retrospective data collection is noted. However, telephonic follow-ups for ADRs would require explicit ethical approval and consent, which is not discussed. In addition, the study setting (rural tertiary care hospital) is described, but the representativeness of the sample for broader populations (e.g., urban or primary care settings) is unclear.

5. Peer review responses: The authors’ responses to reviewers (e.g., sample size recalculation, ADR methodology) are superficial. Key critiques (e.g., hospital vs. community UTI distinction, statistical methods) remain unaddressed. Moreover, the introduction and discussion sections lack critical synthesis of prior literature (e.g., regional antibiotic resistance trends in Central India).

6. Statistical analysis: The description of statistical methods is insufficient. For example: No details on covariates, regression models, or handling missing data. Again, the plan to use chi-square tests and logistic regression is mentioned but not elaborated (e.g., how predictors like age or comorbidity will be incorporated).

7. Clarity and reproducibility: Table 1 (Data Collection) lists parameters but lacks operational definitions (e.g., "irrational prescription" criteria). In addition, the study's retrospective nature limits its ability to capture ADRs accurately, as these are often underreported in hospital records.

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Microbiology

I confirm that I have read this submission and believe that I have an appropriate level of expertise to state that I do not consider it to be of an acceptable scientific standard, for reasons outlined above.

CITE

Report a concern

Author Response 10 Sep 2025

DR. GAYATRI PATIL , Pharmacology, Datta Meghe Institute of Higher Education and Research, Wardha, 442001, India

10 Sep 2025

Author Response
Dear Reviewer,
We sincerely thank you for your thoughtful review and constructive feedback. We carefully revised the manuscript to address your concerns while maintaining the retrospective design already approved by ... Continue reading
Dear Reviewer,
We sincerely thank you for your thoughtful review and constructive feedback. We carefully revised the manuscript to address your concerns while maintaining the retrospective design already approved by the Institutional Ethics Committee. Below, we outline our responses and the corresponding changes made:

1. Study design and methodology

Comment: Contradiction between retrospective design and telephonic follow-up; unclear community vs. hospital-acquired cases; missing diagnostic criteria.

Response: We have clarified that the study is a retrospective observational record-based study only, with no telephonic follow-up or direct patient contact (Methods, Study Design).
We also explicitly state that included cases are community-acquired, uncomplicated UTIs diagnosed by clinical symptoms ± urine culture (Methods, Population and Case Definition).

2. Sample size and statistical power

Comment: Justification remains weak; subgroup analyses underpowered.

Response: The ADR prevalence-based calculation (n=139) has been retained. We added a statement that while subgroup analyses may be underpowered, the sample is adequate for the primary objectives (Methods, Sample Size).

3. Objectives and scope

Comment: Objectives too broad; unclear ADR and FDC evaluation.

Response: Objectives have been refined for precision:

ADRs now specified as “incidence, type, and documented severity.”

FDC evaluation restricted to standard, guideline-recommended combinations (e.g., Co-trimoxazole, Amoxiclav) (Objectives section).

4. Ethical and practical issues

Comment: Waiver of consent unclear; telephonic follow-up ethics not addressed.

Response: We clarified that consent was waived by the IEC since this is retrospective, with no patient contact. Institutional permission was obtained from the Chief Medical Superintendent and Medical Records Section (Ethics section).

5. Statistical analysis

Comment: Methods insufficient; no details on regression or handling missing data.

Response: The Statistical Analysis section has been expanded:

Descriptive statistics for baseline data.

Chi-square for association between drug class and ADRs.

Logistic regression for predictors (age, comorbidity, drug class).

Handling of missing data specified.

SPSS v27 mentioned.

6. Clarity and reproducibility (Table 1)

Comment: Operational definitions missing.

Response: We revised Table 1 to include clear operational definitions for irrational prescription, recurrent UTI, ADR (WHO-UMC), and comorbidity.

7. Introduction and Discussion

Comment: Lack of regional resistance data and critical synthesis.

Response: We acknowledge the reviewer’s suggestion regarding inclusion of regional resistance data and critical synthesis. Our original Introduction and Discussion were drafted to maintain brevity and focus on prescribing trends and ADRs. While we did not insert new sentences in the main text, we have carefully reviewed relevant Central India resistance reports (e.g., Taneja & Sharma, 2019; Dutta et al., 2023) and confirm that our findings are consistent with these patterns. To preserve flow and word limits, these data have been emphasized in our response here rather than in the manuscript body.
Dear Reviewer,
We sincerely thank you for your thoughtful review and constructive feedback. We carefully revised the manuscript to address your concerns while maintaining the retrospective design already approved by the Institutional Ethics Committee. Below, we outline our responses and the corresponding changes made:

1. Study design and methodology

Comment: Contradiction between retrospective design and telephonic follow-up; unclear community vs. hospital-acquired cases; missing diagnostic criteria.

Response: We have clarified that the study is a retrospective observational record-based study only, with no telephonic follow-up or direct patient contact (Methods, Study Design).
We also explicitly state that included cases are community-acquired, uncomplicated UTIs diagnosed by clinical symptoms ± urine culture (Methods, Population and Case Definition).

2. Sample size and statistical power

Comment: Justification remains weak; subgroup analyses underpowered.

Response: The ADR prevalence-based calculation (n=139) has been retained. We added a statement that while subgroup analyses may be underpowered, the sample is adequate for the primary objectives (Methods, Sample Size).

3. Objectives and scope

Comment: Objectives too broad; unclear ADR and FDC evaluation.

Response: Objectives have been refined for precision:

ADRs now specified as “incidence, type, and documented severity.”

FDC evaluation restricted to standard, guideline-recommended combinations (e.g., Co-trimoxazole, Amoxiclav) (Objectives section).

4. Ethical and practical issues

Comment: Waiver of consent unclear; telephonic follow-up ethics not addressed.

Response: We clarified that consent was waived by the IEC since this is retrospective, with no patient contact. Institutional permission was obtained from the Chief Medical Superintendent and Medical Records Section (Ethics section).

5. Statistical analysis

Comment: Methods insufficient; no details on regression or handling missing data.

Response: The Statistical Analysis section has been expanded:

Descriptive statistics for baseline data.

Chi-square for association between drug class and ADRs.

Logistic regression for predictors (age, comorbidity, drug class).

Handling of missing data specified.

SPSS v27 mentioned.

6. Clarity and reproducibility (Table 1)

Comment: Operational definitions missing.

Response: We revised Table 1 to include clear operational definitions for irrational prescription, recurrent UTI, ADR (WHO-UMC), and comorbidity.

7. Introduction and Discussion

Comment: Lack of regional resistance data and critical synthesis.

Response: We acknowledge the reviewer’s suggestion regarding inclusion of regional resistance data and critical synthesis. Our original Introduction and Discussion were drafted to maintain brevity and focus on prescribing trends and ADRs. While we did not insert new sentences in the main text, we have carefully reviewed relevant Central India resistance reports (e.g., Taneja & Sharma, 2019; Dutta et al., 2023) and confirm that our findings are consistent with these patterns. To preserve flow and word limits, these data have been emphasized in our response here rather than in the manuscript body.
Competing Interests: No competing interests were disclosed. Close
Report a concern
Respond or Comment

COMMENTS ON THIS REPORT

Author Response 10 Sep 2025

DR. GAYATRI PATIL , Pharmacology, Datta Meghe Institute of Higher Education and Research, Wardha, 442001, India

10 Sep 2025

Author Response
Dear Reviewer,
We sincerely thank you for your thoughtful review and constructive feedback. We carefully revised the manuscript to address your concerns while maintaining the retrospective design already approved by ... Continue reading
Dear Reviewer,
We sincerely thank you for your thoughtful review and constructive feedback. We carefully revised the manuscript to address your concerns while maintaining the retrospective design already approved by the Institutional Ethics Committee. Below, we outline our responses and the corresponding changes made:

1. Study design and methodology

Comment: Contradiction between retrospective design and telephonic follow-up; unclear community vs. hospital-acquired cases; missing diagnostic criteria.

Response: We have clarified that the study is a retrospective observational record-based study only, with no telephonic follow-up or direct patient contact (Methods, Study Design).
We also explicitly state that included cases are community-acquired, uncomplicated UTIs diagnosed by clinical symptoms ± urine culture (Methods, Population and Case Definition).

2. Sample size and statistical power

Comment: Justification remains weak; subgroup analyses underpowered.

Response: The ADR prevalence-based calculation (n=139) has been retained. We added a statement that while subgroup analyses may be underpowered, the sample is adequate for the primary objectives (Methods, Sample Size).

3. Objectives and scope

Comment: Objectives too broad; unclear ADR and FDC evaluation.

Response: Objectives have been refined for precision:

ADRs now specified as “incidence, type, and documented severity.”

FDC evaluation restricted to standard, guideline-recommended combinations (e.g., Co-trimoxazole, Amoxiclav) (Objectives section).

4. Ethical and practical issues

Comment: Waiver of consent unclear; telephonic follow-up ethics not addressed.

Response: We clarified that consent was waived by the IEC since this is retrospective, with no patient contact. Institutional permission was obtained from the Chief Medical Superintendent and Medical Records Section (Ethics section).

5. Statistical analysis

Comment: Methods insufficient; no details on regression or handling missing data.

Response: The Statistical Analysis section has been expanded:

Descriptive statistics for baseline data.

Chi-square for association between drug class and ADRs.

Logistic regression for predictors (age, comorbidity, drug class).

Handling of missing data specified.

SPSS v27 mentioned.

6. Clarity and reproducibility (Table 1)

Comment: Operational definitions missing.

Response: We revised Table 1 to include clear operational definitions for irrational prescription, recurrent UTI, ADR (WHO-UMC), and comorbidity.

7. Introduction and Discussion

Comment: Lack of regional resistance data and critical synthesis.

Response: We acknowledge the reviewer’s suggestion regarding inclusion of regional resistance data and critical synthesis. Our original Introduction and Discussion were drafted to maintain brevity and focus on prescribing trends and ADRs. While we did not insert new sentences in the main text, we have carefully reviewed relevant Central India resistance reports (e.g., Taneja & Sharma, 2019; Dutta et al., 2023) and confirm that our findings are consistent with these patterns. To preserve flow and word limits, these data have been emphasized in our response here rather than in the manuscript body.
Dear Reviewer,
We sincerely thank you for your thoughtful review and constructive feedback. We carefully revised the manuscript to address your concerns while maintaining the retrospective design already approved by the Institutional Ethics Committee. Below, we outline our responses and the corresponding changes made:

1. Study design and methodology

Comment: Contradiction between retrospective design and telephonic follow-up; unclear community vs. hospital-acquired cases; missing diagnostic criteria.

Response: We have clarified that the study is a retrospective observational record-based study only, with no telephonic follow-up or direct patient contact (Methods, Study Design).
We also explicitly state that included cases are community-acquired, uncomplicated UTIs diagnosed by clinical symptoms ± urine culture (Methods, Population and Case Definition).

2. Sample size and statistical power

Comment: Justification remains weak; subgroup analyses underpowered.

Response: The ADR prevalence-based calculation (n=139) has been retained. We added a statement that while subgroup analyses may be underpowered, the sample is adequate for the primary objectives (Methods, Sample Size).

3. Objectives and scope

Comment: Objectives too broad; unclear ADR and FDC evaluation.

Response: Objectives have been refined for precision:

ADRs now specified as “incidence, type, and documented severity.”

FDC evaluation restricted to standard, guideline-recommended combinations (e.g., Co-trimoxazole, Amoxiclav) (Objectives section).

4. Ethical and practical issues

Comment: Waiver of consent unclear; telephonic follow-up ethics not addressed.

Response: We clarified that consent was waived by the IEC since this is retrospective, with no patient contact. Institutional permission was obtained from the Chief Medical Superintendent and Medical Records Section (Ethics section).

5. Statistical analysis

Comment: Methods insufficient; no details on regression or handling missing data.

Response: The Statistical Analysis section has been expanded:

Descriptive statistics for baseline data.

Chi-square for association between drug class and ADRs.

Logistic regression for predictors (age, comorbidity, drug class).

Handling of missing data specified.

SPSS v27 mentioned.

6. Clarity and reproducibility (Table 1)

Comment: Operational definitions missing.

Response: We revised Table 1 to include clear operational definitions for irrational prescription, recurrent UTI, ADR (WHO-UMC), and comorbidity.

7. Introduction and Discussion

Comment: Lack of regional resistance data and critical synthesis.

Response: We acknowledge the reviewer’s suggestion regarding inclusion of regional resistance data and critical synthesis. Our original Introduction and Discussion were drafted to maintain brevity and focus on prescribing trends and ADRs. While we did not insert new sentences in the main text, we have carefully reviewed relevant Central India resistance reports (e.g., Taneja & Sharma, 2019; Dutta et al., 2023) and confirm that our findings are consistent with these patterns. To preserve flow and word limits, these data have been emphasized in our response here rather than in the manuscript body.
Competing Interests: No competing interests were disclosed. Close
Report a concern

Views

Reviewer Report 13 Aug 2025

Niels Frimodt-Møller, Copenhagen University Hospital, Copenhagen, Denmark

Approved

https://doi.org/10.5256/f1000research.185974.r402774

The authors have responded adequately ... Continue reading

CITE

Report a concern

Respond or Comment

Version 2

VERSION 2

PUBLISHED 11 Feb 2025

Revised

Views

Reviewer Report 28 Jul 2025

Abayeneh Girma, Mekdela Amba University, Tulu Awlya, South Wollo Zone, Ethiopia

Not Approved

https://doi.org/10.5256/f1000research.176032.r399331

General comments
The manuscript addresses an important topic—prescription patterns and adverse drug reactions (ADRs) in urinary tract infections (UTIs) among reproductive-age women. However, significant methodological and conceptual flaws persist despite revisions, as highlighted by previous reviewers. The study’s ... Continue reading

General comments
The manuscript addresses an important topic—prescription patterns and adverse drug reactions (ADRs) in urinary tract infections (UTIs) among reproductive-age women. However, significant methodological and conceptual flaws persist despite revisions, as highlighted by previous reviewers. The study’s design, sample size justification, and clarity of objectives remain inadequate, compromising its scientific rigor and reproducibility.
Major comments

Sample size and statistical power: The sample size calculation (n=47) is based on UTI prevalence (3.14%) rather than ADR prevalence (typically 5–15%), as correctly noted by Reviewer 1. This undermines the study’s ability to detect meaningful ADR patterns. A sample size of 47 is insufficient for robust conclusions, especially for secondary outcomes like combination therapy analysis.
Study design and methodology (i) Retrospective vs. prospective contradictions: The authors claim a retrospective design but propose telephonic follow-ups for ADR data, which introduces prospective elements. This hybrid approach lacks justification and risks bias (e.g., recall bias, non-response bias). (ii) Data source clarity: The manuscript does not specify whether UTIs are community-acquired or hospital-acquired, nor does it define diagnostic criteria (e.g., symptoms, culture results). This omission limits the interpretability of prescription patterns. (iii) ADR collection: Relying on hospital records for ADRs is problematic, as ADRs are often underreported in retrospective data. The plan to contact patients by phone is not standardized or ethically clarified (e.g., consent process).
Objectives and scope: The primary objectives are clear but overly broad. For example, "analyzing adverse reactions" lacks specificity (e.g., which ADRs, severity grading). Again, the secondary objective to analyze fixed-dose combinations (FDCs) is commendable but poorly operationalized. Examples like "Nitrofurantoin + Vitamin B6" are questionable, as Vitamin B6 is not a standard UTI treatment.
Peer review responses: The authors’ responses to reviewers (e.g., sample size recalculation, ADR methodology) are superficial. Key critiques (e.g., hospital vs. community UTI distinction, statistical methods) remain unaddressed.
Ethical and practical issues: While ethical approval is mentioned, the waiver for patient consent in retrospective data collection is noted. However, telephonic follow-ups for ADRs would require explicit ethical approval and consent, which is not discussed.

Minor comments

Introduction/Discussion: Redundant and lacks critical synthesis of prior literature (e.g., no mention of regional antibiotic resistance trends in Central India).
Table 1 (Data Collection): Parameters are listed but lack operational definitions (e.g., "irrational prescription" criteria).
Statistical analysis: Mention of "Student’s t-test and Chi-square" is insufficient. No details on covariates, regression models, or handling missing data.

Is the rationale for, and objectives of, the study clearly described?

No
Is the study design appropriate for the research question?

No
Are sufficient details of the methods provided to allow replication by others?

No
Are the datasets clearly presented in a useable and accessible format?

No

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Microbiology

CITE

Report a concern

Author Response 09 Aug 2025

DR. GAYATRI PATIL , Pharmacology, Datta Meghe Institute of Higher Education and Research, Wardha, 442001, India

09 Aug 2025

Author Response

Response to Reviewer: Dr. Niels Frimodt-Møller
COMMENT 1:
“The calculation of sample size is not correct; With a prevalence of around 3% (and what does that mean?) of UTIs in ... Continue reading Response to Reviewer: Dr. Niels Frimodt-Møller
COMMENT 1:
“The calculation of sample size is not correct; With a prevalence of around 3% (and what does that mean?) of UTIs in India they propose, that 47 patients will suffice? The prevalence of adverse effects is probably 10-15%; the investigators will need at least 10 times as many patients to achieve a reasonable result.”
AUTHOR RESPONSE:
We thank the reviewer for this important observation. We agree that calculating sample size based on UTI prevalence was not appropriate for our primary objective, which includes the analysis of adverse drug reactions (ADRs).
In response, we have recalculated the sample size using Daniel’s formula, based on an assumed ADR prevalence of 10%, with 95% confidence level and a 5% margin of error.
Formula used:
n = Z² × P × (1 − P) / d²
Z = 1.96, P = 0.10, d = 0.05
n = (1.96)² × 0.10 × (0.90) / (0.05)² ≈ 138.3
We have therefore revised the sample size to 139 patients and updated this in the Sample Size Estimation section. This revised sample size is now aligned with our primary outcome — the analysis of adverse drug reactions. We used an assumed ADR prevalence of 10%, as reported in similar studies (e.g., Fatima et al., J Drug Deliv Ther, 2015). This reference has been cited in the updated manuscript to support our methodology.

COMMENT 2:
The method to study adverse effects is to look in the charts (response to reviewer 1), while they also want to call by phone the patients in question (response to reviewer 2); in the last case it is not a retrospective study. Which charts are we talking about? If hospital charts, then the patients belong to a special group of patients admitted to hospital probably with complicated UTI, where adverse effects are different from community dwellers with uncomplicated UTI.
AUTHOR RESPONSE:
Thank you for pointing out this inconsistency. We have now removed the telephonic follow-up plan and clarified that the study will be conducted as a purely retrospective observational study. Only medical records from the hospital’s archived data will be used.
The protocol has been updated to reflect this in the Study Design, Data Collection, and Ethical Considerations sections. We will rely solely on documented ADRs recorded in the patient files.
This revision ensures methodological consistency with retrospective design principles and aligns with the ethical waiver granted by our Institutional Ethics Committee.

We have now specified that our data will be collected only from outpatient department (OPD) records of women diagnosed and treated for UTI. This ensures that our focus is on community-acquired, uncomplicated UTIs.
This clarification is now included in the Study Setting, Inclusion Criteria, and Data Collection sections. No inpatient or ICU cases will be included, and complicated UTI cases will be excluded.

COMMENT 3:
The introduction has not been revised as proposed by reviewer 1, and neither the discussion as also recommended.
AUTHOR RESPONSE:
We thank the reviewer for this feedback. We have now extensively revised both the Introduction and Discussion sections.
The Introduction now includes recent literature on UTI treatment patterns, local prescribing practices, and rationale for ADR monitoring in reproductive-age women.
The Discussion has been expanded to address implications of irrational prescribing, potential underreporting of ADRs, and the regional significance of our findings. We have also added a paragraph on study limitations to improve transparency.
All changes are clearly marked in the revised manuscript.

COMMENT 4:
The different treatments of UTI described in the protocol are mostly for uncomplicated UTI, which does not comply with the idea, that hospital charts are being scrutinized.
AUTHOR RESPONSE:
As noted above, we have now explicitly stated that the study will include only outpatient records, and our focus is on community-acquired uncomplicated UTIs.
Accordingly, the treatment guidelines referenced in the manuscript pertain to uncomplicated UTI management, and this is now clearly stated in the revised Treatment and Study Design sections.
Response to Reviewer: Dr. Niels Frimodt-Møller
COMMENT 1:
“The calculation of sample size is not correct; With a prevalence of around 3% (and what does that mean?) of UTIs in India they propose, that 47 patients will suffice? The prevalence of adverse effects is probably 10-15%; the investigators will need at least 10 times as many patients to achieve a reasonable result.”
AUTHOR RESPONSE:
We thank the reviewer for this important observation. We agree that calculating sample size based on UTI prevalence was not appropriate for our primary objective, which includes the analysis of adverse drug reactions (ADRs).
In response, we have recalculated the sample size using Daniel’s formula, based on an assumed ADR prevalence of 10%, with 95% confidence level and a 5% margin of error.
Formula used:
n = Z² × P × (1 − P) / d²
Z = 1.96, P = 0.10, d = 0.05
n = (1.96)² × 0.10 × (0.90) / (0.05)² ≈ 138.3
We have therefore revised the sample size to 139 patients and updated this in the Sample Size Estimation section. This revised sample size is now aligned with our primary outcome — the analysis of adverse drug reactions. We used an assumed ADR prevalence of 10%, as reported in similar studies (e.g., Fatima et al., J Drug Deliv Ther, 2015). This reference has been cited in the updated manuscript to support our methodology.

COMMENT 2:
The method to study adverse effects is to look in the charts (response to reviewer 1), while they also want to call by phone the patients in question (response to reviewer 2); in the last case it is not a retrospective study. Which charts are we talking about? If hospital charts, then the patients belong to a special group of patients admitted to hospital probably with complicated UTI, where adverse effects are different from community dwellers with uncomplicated UTI.
AUTHOR RESPONSE:
Thank you for pointing out this inconsistency. We have now removed the telephonic follow-up plan and clarified that the study will be conducted as a purely retrospective observational study. Only medical records from the hospital’s archived data will be used.
The protocol has been updated to reflect this in the Study Design, Data Collection, and Ethical Considerations sections. We will rely solely on documented ADRs recorded in the patient files.
This revision ensures methodological consistency with retrospective design principles and aligns with the ethical waiver granted by our Institutional Ethics Committee.

We have now specified that our data will be collected only from outpatient department (OPD) records of women diagnosed and treated for UTI. This ensures that our focus is on community-acquired, uncomplicated UTIs.
This clarification is now included in the Study Setting, Inclusion Criteria, and Data Collection sections. No inpatient or ICU cases will be included, and complicated UTI cases will be excluded.

COMMENT 3:
The introduction has not been revised as proposed by reviewer 1, and neither the discussion as also recommended.
AUTHOR RESPONSE:
We thank the reviewer for this feedback. We have now extensively revised both the Introduction and Discussion sections.
The Introduction now includes recent literature on UTI treatment patterns, local prescribing practices, and rationale for ADR monitoring in reproductive-age women.
The Discussion has been expanded to address implications of irrational prescribing, potential underreporting of ADRs, and the regional significance of our findings. We have also added a paragraph on study limitations to improve transparency.
All changes are clearly marked in the revised manuscript.

COMMENT 4:
The different treatments of UTI described in the protocol are mostly for uncomplicated UTI, which does not comply with the idea, that hospital charts are being scrutinized.
AUTHOR RESPONSE:
As noted above, we have now explicitly stated that the study will include only outpatient records, and our focus is on community-acquired uncomplicated UTIs.
Accordingly, the treatment guidelines referenced in the manuscript pertain to uncomplicated UTI management, and this is now clearly stated in the revised Treatment and Study Design sections.
Competing Interests: No competing interests were disclosed. Close
Report a concern
Respond or Comment

COMMENTS ON THIS REPORT

Author Response 09 Aug 2025

DR. GAYATRI PATIL , Pharmacology, Datta Meghe Institute of Higher Education and Research, Wardha, 442001, India

09 Aug 2025

Author Response

Response to Reviewer: Dr. Niels Frimodt-Møller
COMMENT 1:
“The calculation of sample size is not correct; With a prevalence of around 3% (and what does that mean?) of UTIs in ... Continue reading Response to Reviewer: Dr. Niels Frimodt-Møller
COMMENT 1:
“The calculation of sample size is not correct; With a prevalence of around 3% (and what does that mean?) of UTIs in India they propose, that 47 patients will suffice? The prevalence of adverse effects is probably 10-15%; the investigators will need at least 10 times as many patients to achieve a reasonable result.”
AUTHOR RESPONSE:
We thank the reviewer for this important observation. We agree that calculating sample size based on UTI prevalence was not appropriate for our primary objective, which includes the analysis of adverse drug reactions (ADRs).
In response, we have recalculated the sample size using Daniel’s formula, based on an assumed ADR prevalence of 10%, with 95% confidence level and a 5% margin of error.
Formula used:
n = Z² × P × (1 − P) / d²
Z = 1.96, P = 0.10, d = 0.05
n = (1.96)² × 0.10 × (0.90) / (0.05)² ≈ 138.3
We have therefore revised the sample size to 139 patients and updated this in the Sample Size Estimation section. This revised sample size is now aligned with our primary outcome — the analysis of adverse drug reactions. We used an assumed ADR prevalence of 10%, as reported in similar studies (e.g., Fatima et al., J Drug Deliv Ther, 2015). This reference has been cited in the updated manuscript to support our methodology.

COMMENT 2:
The method to study adverse effects is to look in the charts (response to reviewer 1), while they also want to call by phone the patients in question (response to reviewer 2); in the last case it is not a retrospective study. Which charts are we talking about? If hospital charts, then the patients belong to a special group of patients admitted to hospital probably with complicated UTI, where adverse effects are different from community dwellers with uncomplicated UTI.
AUTHOR RESPONSE:
Thank you for pointing out this inconsistency. We have now removed the telephonic follow-up plan and clarified that the study will be conducted as a purely retrospective observational study. Only medical records from the hospital’s archived data will be used.
The protocol has been updated to reflect this in the Study Design, Data Collection, and Ethical Considerations sections. We will rely solely on documented ADRs recorded in the patient files.
This revision ensures methodological consistency with retrospective design principles and aligns with the ethical waiver granted by our Institutional Ethics Committee.

We have now specified that our data will be collected only from outpatient department (OPD) records of women diagnosed and treated for UTI. This ensures that our focus is on community-acquired, uncomplicated UTIs.
This clarification is now included in the Study Setting, Inclusion Criteria, and Data Collection sections. No inpatient or ICU cases will be included, and complicated UTI cases will be excluded.

COMMENT 3:
The introduction has not been revised as proposed by reviewer 1, and neither the discussion as also recommended.
AUTHOR RESPONSE:
We thank the reviewer for this feedback. We have now extensively revised both the Introduction and Discussion sections.
The Introduction now includes recent literature on UTI treatment patterns, local prescribing practices, and rationale for ADR monitoring in reproductive-age women.
The Discussion has been expanded to address implications of irrational prescribing, potential underreporting of ADRs, and the regional significance of our findings. We have also added a paragraph on study limitations to improve transparency.
All changes are clearly marked in the revised manuscript.

COMMENT 4:
The different treatments of UTI described in the protocol are mostly for uncomplicated UTI, which does not comply with the idea, that hospital charts are being scrutinized.
AUTHOR RESPONSE:
As noted above, we have now explicitly stated that the study will include only outpatient records, and our focus is on community-acquired uncomplicated UTIs.
Accordingly, the treatment guidelines referenced in the manuscript pertain to uncomplicated UTI management, and this is now clearly stated in the revised Treatment and Study Design sections.
Response to Reviewer: Dr. Niels Frimodt-Møller
COMMENT 1:
“The calculation of sample size is not correct; With a prevalence of around 3% (and what does that mean?) of UTIs in India they propose, that 47 patients will suffice? The prevalence of adverse effects is probably 10-15%; the investigators will need at least 10 times as many patients to achieve a reasonable result.”
AUTHOR RESPONSE:
We thank the reviewer for this important observation. We agree that calculating sample size based on UTI prevalence was not appropriate for our primary objective, which includes the analysis of adverse drug reactions (ADRs).
In response, we have recalculated the sample size using Daniel’s formula, based on an assumed ADR prevalence of 10%, with 95% confidence level and a 5% margin of error.
Formula used:
n = Z² × P × (1 − P) / d²
Z = 1.96, P = 0.10, d = 0.05
n = (1.96)² × 0.10 × (0.90) / (0.05)² ≈ 138.3
We have therefore revised the sample size to 139 patients and updated this in the Sample Size Estimation section. This revised sample size is now aligned with our primary outcome — the analysis of adverse drug reactions. We used an assumed ADR prevalence of 10%, as reported in similar studies (e.g., Fatima et al., J Drug Deliv Ther, 2015). This reference has been cited in the updated manuscript to support our methodology.

COMMENT 2:
The method to study adverse effects is to look in the charts (response to reviewer 1), while they also want to call by phone the patients in question (response to reviewer 2); in the last case it is not a retrospective study. Which charts are we talking about? If hospital charts, then the patients belong to a special group of patients admitted to hospital probably with complicated UTI, where adverse effects are different from community dwellers with uncomplicated UTI.
AUTHOR RESPONSE:
Thank you for pointing out this inconsistency. We have now removed the telephonic follow-up plan and clarified that the study will be conducted as a purely retrospective observational study. Only medical records from the hospital’s archived data will be used.
The protocol has been updated to reflect this in the Study Design, Data Collection, and Ethical Considerations sections. We will rely solely on documented ADRs recorded in the patient files.
This revision ensures methodological consistency with retrospective design principles and aligns with the ethical waiver granted by our Institutional Ethics Committee.

We have now specified that our data will be collected only from outpatient department (OPD) records of women diagnosed and treated for UTI. This ensures that our focus is on community-acquired, uncomplicated UTIs.
This clarification is now included in the Study Setting, Inclusion Criteria, and Data Collection sections. No inpatient or ICU cases will be included, and complicated UTI cases will be excluded.

COMMENT 3:
The introduction has not been revised as proposed by reviewer 1, and neither the discussion as also recommended.
AUTHOR RESPONSE:
We thank the reviewer for this feedback. We have now extensively revised both the Introduction and Discussion sections.
The Introduction now includes recent literature on UTI treatment patterns, local prescribing practices, and rationale for ADR monitoring in reproductive-age women.
The Discussion has been expanded to address implications of irrational prescribing, potential underreporting of ADRs, and the regional significance of our findings. We have also added a paragraph on study limitations to improve transparency.
All changes are clearly marked in the revised manuscript.

COMMENT 4:
The different treatments of UTI described in the protocol are mostly for uncomplicated UTI, which does not comply with the idea, that hospital charts are being scrutinized.
AUTHOR RESPONSE:
As noted above, we have now explicitly stated that the study will include only outpatient records, and our focus is on community-acquired uncomplicated UTIs.
Accordingly, the treatment guidelines referenced in the manuscript pertain to uncomplicated UTI management, and this is now clearly stated in the revised Treatment and Study Design sections.
Competing Interests: No competing interests were disclosed. Close
Report a concern

Views

Reviewer Report 13 Feb 2025

Niels Frimodt-Møller, Copenhagen University Hospital, Copenhagen, Denmark

Not Approved

https://doi.org/10.5256/f1000research.176032.r365731

The authors' responses to the reviewers' suggestions seem a bit unclear, and it appears that my original comments may not have been fully addressed.

The calculation of sample size is not correct; With a prevalence of

The authors' responses to the reviewers' suggestions seem a bit unclear, and it appears that my original comments may not have been fully addressed.

The calculation of sample size is not correct; With a prevalence of around 3% (and what does that mean?) of UTIs in India they propose, that 47 patients will suffice? The prevalence of adverse effects is probably 10-15 %; the investigators will need at least 10 times as many patients to achieve a reasonable results.
The method to study adverse effects is to look in the charts (response to reviewer 1), while they also want to call by phone the patients in question (response to reviewer 2); in the last case it is not a retrospective study. Which charts are we talking about? If hospital charts, then the patients belong to a special group of patients admitted to hospital probably with complicated UTI, where adverse effects are different from community dwellers with uncomplicated UTI.
The introduction has not been revised as proposed by reviewer 1, and neither the discussion as also recommended.
The different treatments of UTI described in the protocol are mostly for uncomplicated UTI, which does not comply with the idea, that hospital charts are being scrutinized.
The authors need to respond to the comments and completely revise the protocol.

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Clinical microbiology, urinary tract infections, E.coli pathogenesis, antibiotic activity in vitro and in vivo

CITE

Report a concern

Author Response 09 Aug 2025

DR. GAYATRI PATIL , Pharmacology, Datta Meghe Institute of Higher Education and Research, Wardha, 442001, India

09 Aug 2025

Author Response

Response to Reviewer: Dr. Niels Frimodt-Møller
COMMENT 1:
“The calculation of sample size is not correct; With a prevalence of around 3% (and what does that mean?) of UTIs in ... Continue reading Response to Reviewer: Dr. Niels Frimodt-Møller
COMMENT 1:
“The calculation of sample size is not correct; With a prevalence of around 3% (and what does that mean?) of UTIs in India they propose, that 47 patients will suffice? The prevalence of adverse effects is probably 10-15%; the investigators will need at least 10 times as many patients to achieve a reasonable result.”
AUTHOR RESPONSE:
We thank the reviewer for this important observation. We agree that calculating sample size based on UTI prevalence was not appropriate for our primary objective, which includes the analysis of adverse drug reactions (ADRs).
In response, we have recalculated the sample size using Daniel’s formula, based on an assumed ADR prevalence of 10%, with 95% confidence level and a 5% margin of error.
Formula used:
n = Z² × P × (1 − P) / d²
Z = 1.96, P = 0.10, d = 0.05
n = (1.96)² × 0.10 × (0.90) / (0.05)² ≈ 138.3
We have therefore revised the sample size to 139 patients and updated this in the Sample Size Estimation section. This revised sample size is now aligned with our primary outcome — the analysis of adverse drug reactions. We used an assumed ADR prevalence of 10%, as reported in similar studies (e.g., Fatima et al., J Drug Deliv Ther, 2015). This reference has been cited in the updated manuscript to support our methodology.

COMMENT 2:
The method to study adverse effects is to look in the charts (response to reviewer 1), while they also want to call by phone the patients in question (response to reviewer 2); in the last case it is not a retrospective study. Which charts are we talking about? If hospital charts, then the patients belong to a special group of patients admitted to hospital probably with complicated UTI, where adverse effects are different from community dwellers with uncomplicated UTI.
AUTHOR RESPONSE:
Thank you for pointing out this inconsistency. We have now removed the telephonic follow-up plan and clarified that the study will be conducted as a purely retrospective observational study. Only medical records from the hospital’s archived data will be used.
The protocol has been updated to reflect this in the Study Design, Data Collection, and Ethical Considerations sections. We will rely solely on documented ADRs recorded in the patient files.
This revision ensures methodological consistency with retrospective design principles and aligns with the ethical waiver granted by our Institutional Ethics Committee.

We have now specified that our data will be collected only from outpatient department (OPD) records of women diagnosed and treated for UTI. This ensures that our focus is on community-acquired, uncomplicated UTIs.
This clarification is now included in the Study Setting, Inclusion Criteria, and Data Collection sections. No inpatient or ICU cases will be included, and complicated UTI cases will be excluded.

COMMENT 3:
The introduction has not been revised as proposed by reviewer 1, and neither the discussion as also recommended.
AUTHOR RESPONSE:
We thank the reviewer for this feedback. We have now extensively revised both the Introduction and Discussion sections.
The Introduction now includes recent literature on UTI treatment patterns, local prescribing practices, and rationale for ADR monitoring in reproductive-age women.
The Discussion has been expanded to address implications of irrational prescribing, potential underreporting of ADRs, and the regional significance of our findings. We have also added a paragraph on study limitations to improve transparency.
All changes are clearly marked in the revised manuscript.

COMMENT 4:
The different treatments of UTI described in the protocol are mostly for uncomplicated UTI, which does not comply with the idea, that hospital charts are being scrutinized.
AUTHOR RESPONSE:
As noted above, we have now explicitly stated that the study will include only outpatient records, and our focus is on community-acquired uncomplicated UTIs.
Accordingly, the treatment guidelines referenced in the manuscript pertain to uncomplicated UTI management, and this is now clearly stated in the revised Treatment and Study Design sections.
Response to Reviewer: Dr. Niels Frimodt-Møller
COMMENT 1:
“The calculation of sample size is not correct; With a prevalence of around 3% (and what does that mean?) of UTIs in India they propose, that 47 patients will suffice? The prevalence of adverse effects is probably 10-15%; the investigators will need at least 10 times as many patients to achieve a reasonable result.”
AUTHOR RESPONSE:
We thank the reviewer for this important observation. We agree that calculating sample size based on UTI prevalence was not appropriate for our primary objective, which includes the analysis of adverse drug reactions (ADRs).
In response, we have recalculated the sample size using Daniel’s formula, based on an assumed ADR prevalence of 10%, with 95% confidence level and a 5% margin of error.
Formula used:
n = Z² × P × (1 − P) / d²
Z = 1.96, P = 0.10, d = 0.05
n = (1.96)² × 0.10 × (0.90) / (0.05)² ≈ 138.3
We have therefore revised the sample size to 139 patients and updated this in the Sample Size Estimation section. This revised sample size is now aligned with our primary outcome — the analysis of adverse drug reactions. We used an assumed ADR prevalence of 10%, as reported in similar studies (e.g., Fatima et al., J Drug Deliv Ther, 2015). This reference has been cited in the updated manuscript to support our methodology.

COMMENT 2:
The method to study adverse effects is to look in the charts (response to reviewer 1), while they also want to call by phone the patients in question (response to reviewer 2); in the last case it is not a retrospective study. Which charts are we talking about? If hospital charts, then the patients belong to a special group of patients admitted to hospital probably with complicated UTI, where adverse effects are different from community dwellers with uncomplicated UTI.
AUTHOR RESPONSE:
Thank you for pointing out this inconsistency. We have now removed the telephonic follow-up plan and clarified that the study will be conducted as a purely retrospective observational study. Only medical records from the hospital’s archived data will be used.
The protocol has been updated to reflect this in the Study Design, Data Collection, and Ethical Considerations sections. We will rely solely on documented ADRs recorded in the patient files.
This revision ensures methodological consistency with retrospective design principles and aligns with the ethical waiver granted by our Institutional Ethics Committee.

We have now specified that our data will be collected only from outpatient department (OPD) records of women diagnosed and treated for UTI. This ensures that our focus is on community-acquired, uncomplicated UTIs.
This clarification is now included in the Study Setting, Inclusion Criteria, and Data Collection sections. No inpatient or ICU cases will be included, and complicated UTI cases will be excluded.

COMMENT 3:
The introduction has not been revised as proposed by reviewer 1, and neither the discussion as also recommended.
AUTHOR RESPONSE:
We thank the reviewer for this feedback. We have now extensively revised both the Introduction and Discussion sections.
The Introduction now includes recent literature on UTI treatment patterns, local prescribing practices, and rationale for ADR monitoring in reproductive-age women.
The Discussion has been expanded to address implications of irrational prescribing, potential underreporting of ADRs, and the regional significance of our findings. We have also added a paragraph on study limitations to improve transparency.
All changes are clearly marked in the revised manuscript.

COMMENT 4:
The different treatments of UTI described in the protocol are mostly for uncomplicated UTI, which does not comply with the idea, that hospital charts are being scrutinized.
AUTHOR RESPONSE:
As noted above, we have now explicitly stated that the study will include only outpatient records, and our focus is on community-acquired uncomplicated UTIs.
Accordingly, the treatment guidelines referenced in the manuscript pertain to uncomplicated UTI management, and this is now clearly stated in the revised Treatment and Study Design sections.
Competing Interests: No competing interests were disclosed. Close
Report a concern
Respond or Comment

COMMENTS ON THIS REPORT

Author Response 09 Aug 2025

DR. GAYATRI PATIL , Pharmacology, Datta Meghe Institute of Higher Education and Research, Wardha, 442001, India

09 Aug 2025

Author Response

Response to Reviewer: Dr. Niels Frimodt-Møller
COMMENT 1:
“The calculation of sample size is not correct; With a prevalence of around 3% (and what does that mean?) of UTIs in ... Continue reading Response to Reviewer: Dr. Niels Frimodt-Møller
COMMENT 1:
“The calculation of sample size is not correct; With a prevalence of around 3% (and what does that mean?) of UTIs in India they propose, that 47 patients will suffice? The prevalence of adverse effects is probably 10-15%; the investigators will need at least 10 times as many patients to achieve a reasonable result.”
AUTHOR RESPONSE:
We thank the reviewer for this important observation. We agree that calculating sample size based on UTI prevalence was not appropriate for our primary objective, which includes the analysis of adverse drug reactions (ADRs).
In response, we have recalculated the sample size using Daniel’s formula, based on an assumed ADR prevalence of 10%, with 95% confidence level and a 5% margin of error.
Formula used:
n = Z² × P × (1 − P) / d²
Z = 1.96, P = 0.10, d = 0.05
n = (1.96)² × 0.10 × (0.90) / (0.05)² ≈ 138.3
We have therefore revised the sample size to 139 patients and updated this in the Sample Size Estimation section. This revised sample size is now aligned with our primary outcome — the analysis of adverse drug reactions. We used an assumed ADR prevalence of 10%, as reported in similar studies (e.g., Fatima et al., J Drug Deliv Ther, 2015). This reference has been cited in the updated manuscript to support our methodology.

COMMENT 2:
The method to study adverse effects is to look in the charts (response to reviewer 1), while they also want to call by phone the patients in question (response to reviewer 2); in the last case it is not a retrospective study. Which charts are we talking about? If hospital charts, then the patients belong to a special group of patients admitted to hospital probably with complicated UTI, where adverse effects are different from community dwellers with uncomplicated UTI.
AUTHOR RESPONSE:
Thank you for pointing out this inconsistency. We have now removed the telephonic follow-up plan and clarified that the study will be conducted as a purely retrospective observational study. Only medical records from the hospital’s archived data will be used.
The protocol has been updated to reflect this in the Study Design, Data Collection, and Ethical Considerations sections. We will rely solely on documented ADRs recorded in the patient files.
This revision ensures methodological consistency with retrospective design principles and aligns with the ethical waiver granted by our Institutional Ethics Committee.

We have now specified that our data will be collected only from outpatient department (OPD) records of women diagnosed and treated for UTI. This ensures that our focus is on community-acquired, uncomplicated UTIs.
This clarification is now included in the Study Setting, Inclusion Criteria, and Data Collection sections. No inpatient or ICU cases will be included, and complicated UTI cases will be excluded.

COMMENT 3:
The introduction has not been revised as proposed by reviewer 1, and neither the discussion as also recommended.
AUTHOR RESPONSE:
We thank the reviewer for this feedback. We have now extensively revised both the Introduction and Discussion sections.
The Introduction now includes recent literature on UTI treatment patterns, local prescribing practices, and rationale for ADR monitoring in reproductive-age women.
The Discussion has been expanded to address implications of irrational prescribing, potential underreporting of ADRs, and the regional significance of our findings. We have also added a paragraph on study limitations to improve transparency.
All changes are clearly marked in the revised manuscript.

COMMENT 4:
The different treatments of UTI described in the protocol are mostly for uncomplicated UTI, which does not comply with the idea, that hospital charts are being scrutinized.
AUTHOR RESPONSE:
As noted above, we have now explicitly stated that the study will include only outpatient records, and our focus is on community-acquired uncomplicated UTIs.
Accordingly, the treatment guidelines referenced in the manuscript pertain to uncomplicated UTI management, and this is now clearly stated in the revised Treatment and Study Design sections.
Response to Reviewer: Dr. Niels Frimodt-Møller
COMMENT 1:
“The calculation of sample size is not correct; With a prevalence of around 3% (and what does that mean?) of UTIs in India they propose, that 47 patients will suffice? The prevalence of adverse effects is probably 10-15%; the investigators will need at least 10 times as many patients to achieve a reasonable result.”
AUTHOR RESPONSE:
We thank the reviewer for this important observation. We agree that calculating sample size based on UTI prevalence was not appropriate for our primary objective, which includes the analysis of adverse drug reactions (ADRs).
In response, we have recalculated the sample size using Daniel’s formula, based on an assumed ADR prevalence of 10%, with 95% confidence level and a 5% margin of error.
Formula used:
n = Z² × P × (1 − P) / d²
Z = 1.96, P = 0.10, d = 0.05
n = (1.96)² × 0.10 × (0.90) / (0.05)² ≈ 138.3
We have therefore revised the sample size to 139 patients and updated this in the Sample Size Estimation section. This revised sample size is now aligned with our primary outcome — the analysis of adverse drug reactions. We used an assumed ADR prevalence of 10%, as reported in similar studies (e.g., Fatima et al., J Drug Deliv Ther, 2015). This reference has been cited in the updated manuscript to support our methodology.

COMMENT 2:
The method to study adverse effects is to look in the charts (response to reviewer 1), while they also want to call by phone the patients in question (response to reviewer 2); in the last case it is not a retrospective study. Which charts are we talking about? If hospital charts, then the patients belong to a special group of patients admitted to hospital probably with complicated UTI, where adverse effects are different from community dwellers with uncomplicated UTI.
AUTHOR RESPONSE:
Thank you for pointing out this inconsistency. We have now removed the telephonic follow-up plan and clarified that the study will be conducted as a purely retrospective observational study. Only medical records from the hospital’s archived data will be used.
The protocol has been updated to reflect this in the Study Design, Data Collection, and Ethical Considerations sections. We will rely solely on documented ADRs recorded in the patient files.
This revision ensures methodological consistency with retrospective design principles and aligns with the ethical waiver granted by our Institutional Ethics Committee.

We have now specified that our data will be collected only from outpatient department (OPD) records of women diagnosed and treated for UTI. This ensures that our focus is on community-acquired, uncomplicated UTIs.
This clarification is now included in the Study Setting, Inclusion Criteria, and Data Collection sections. No inpatient or ICU cases will be included, and complicated UTI cases will be excluded.

COMMENT 3:
The introduction has not been revised as proposed by reviewer 1, and neither the discussion as also recommended.
AUTHOR RESPONSE:
We thank the reviewer for this feedback. We have now extensively revised both the Introduction and Discussion sections.
The Introduction now includes recent literature on UTI treatment patterns, local prescribing practices, and rationale for ADR monitoring in reproductive-age women.
The Discussion has been expanded to address implications of irrational prescribing, potential underreporting of ADRs, and the regional significance of our findings. We have also added a paragraph on study limitations to improve transparency.
All changes are clearly marked in the revised manuscript.

COMMENT 4:
The different treatments of UTI described in the protocol are mostly for uncomplicated UTI, which does not comply with the idea, that hospital charts are being scrutinized.
AUTHOR RESPONSE:
As noted above, we have now explicitly stated that the study will include only outpatient records, and our focus is on community-acquired uncomplicated UTIs.
Accordingly, the treatment guidelines referenced in the manuscript pertain to uncomplicated UTI management, and this is now clearly stated in the revised Treatment and Study Design sections.
Competing Interests: No competing interests were disclosed. Close
Report a concern

Version 1

VERSION 1

PUBLISHED 29 Apr 2024

Views

Reviewer Report 13 Jul 2024

Vineetha Menon, Gulf Medical University, Ajman, United Arab Emirates

Not Approved

https://doi.org/10.5256/f1000research.163709.r297784

1. Abstract: The abstract is too brief; lacks specificity and content.
2. Introduction: The introduction lacks smooth flow and transitions between sections. There is some redundancy of information, grammatical errors, and formatting issues. There is no information given on the findings from previous studies done in this area. Also, there is a lack of focus on the significance of the study.
3. Method:
a. Study criteria: Study criteria is missing out on several vital elements. For example, details of treatment settings, time frame, presence of comorbidities, pregnancy status, or recurrent infections had not been addressed in the study criteria.
b. What does the author mean by "Study reference: Pritam Pardeshi"?
c. Statistical methods: There is a lack of information on how statistical methods were applied.
d. Dala collection: The data collection process is not detailed enough.
e. Study setting: The study setting does not mention in which institution the study was done.
f. Overall there are a lot of inconsistencies in the methodology. It's also stating that the study will be done- what does that mean?
4. Results: No results are available for review.
5. Discussion: The discussion lacks depth and specificity. There is also repetition of information previously mentioned. No clear conclusion or limitations were stated.

Is the rationale for, and objectives of, the study clearly described?

No
Is the study design appropriate for the research question?

Yes
Are sufficient details of the methods provided to allow replication by others?

No
Are the datasets clearly presented in a useable and accessible format?

No

References

1. Saber S, Yasmin N, Alam M, Hossain M, et al.: Study on Urinary Tract Infection Among Females of Reproductive Age Group in Tertiary Care Teaching Hospital, Dhaka, Bangladesh. European Journal of Medical and Health Sciences. 2021; 3 (1): 85-89 Publisher Full Text
2. Naik S, Samal S, Sahu S, Rath B: Antimicrobial prescribing pattern in urinary tract infection in a tertiary care hospital. National Journal of Physiology, Pharmacy and Pharmacology. 2017. Publisher Full Text
3. Anu Sahaya Supria K, Julliyan Dilleban A: Prescription pattern of antibiotic usage for urinary tract infection in tertiary care hospital. World Journal of Biology Pharmacy and Health Sciences. 2023; 16 (1): 178-181 Publisher Full Text

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Geriatrics, Medication safety management

CITE

Report a concern

Author Response 11 Feb 2025

DR. GAYATRI PATIL , Pharmacology, Datta Meghe Institute of Higher Education and Research, Wardha, 442001, India

11 Feb 2025

Author Response
1. Abstract: The abstract is too brief; lacks specificity and content.
Response: Changes done in the abstract.

2. Introduction: The introduction lacks smooth flow and transitions between sections. There ... Continue reading
1. Abstract: The abstract is too brief; lacks specificity and content.
Response:    Changes done in the abstract.

2. Introduction: The introduction lacks smooth flow and transitions between sections. There is some redundancy of information, grammatical errors, and formatting issues. There is no information given on the findings from previous studies done in this area. Also, there is a lack of focus on the significance of the study.
Response:   Now, I have mentioned the information regarding the previous study. It is mentioned in the discussion part. i.e.
This analysis is for the use of evidence-based medicine in tertiary care centers, to fulfill the drug information needs of the physician and also for improvement in the quality of healthcare by giving feedback to prescribers. This is an observational, retrospective study that will aim at the analysis of drug prescription patterns and adverse drug reactions due to drug prescription in urinary tract infections at tertiary health care centers.

3. Method:
a. Study criteria: Study criteria is missing out on several vital elements. For example, details of treatment settings, time frame, presence of comorbidities, pregnancy status, or recurrent infections had not been addressed in the study criteria.
Response: I have now added these parameters in my annexure
NAME, AGE/SEX, MRD NO., OPD NO., DIAGNOSIS, DRUGS USED, DOSE OF THE DRUG, ANY IRRATIONAL IN PRESCRIPTION, DURATION OF DRUG THERAPY, ADVERSE DRUG REACTIONS, DURATION OF ILLNESS, COMORBIDITIES, PREGNANCY STATUS, RECURRENT INFECTIONS

b. What does the author mean by "Study reference: Pritam Pardeshi"?
Response: This was the reference for my sample size calculation for the study.

c. Statistical methods: There is a lack of information on how statistical methods were applied.
Response: We will use the student’s t-test and Chi-square Test.

d. Data collection: The data collection process is not detailed enough.
Response: I will be collecting the data from the medical record section and then I will analyze the prescription for the given parameters which were given in the data collection section in my protocol.

e. Study setting: The study setting does not mention in which institution the study was done.
Response: This study will be carried out in the Rural Tertiary Care Hospital in Central India

f. Overall there are a lot of inconsistencies in the methodology. It's also stating that the study will be done- what does that mean?
Response: We haven’t started this study yet that’s why I wrote the study will be done. It’s my protocol for my study.

4. Results: No results are available for review.
Response: As this study is not started yet we can’t predict the result of this analysis. That’s why I didn’t mention the results.

5. Discussion: The discussion lacks depth and specificity. There is also a repetition of information previously mentioned. No clear conclusion or limitations were stated.
Response: I have made the changes in the discussion part according to your comments.

Is the rationale for, and objectives of, the study clearly described?

No, now I have made the changes to the objective.

Is the study design appropriate for the research question?

Yes

Are sufficient details of the methods provided to allow replication by others?

No   Response: Changes were made in the data collection section.

Are the datasets clearly presented in a useable and accessible format?

No
Response:   I have mentioned the parameters in this ANNEXURE.
NAME, AGE/SEX, MRD NO., OPD NO., DIAGNOSIS, DRUGS USED, DOSE OF THE DRUG, ANY IRRATIONAL IN PRESCRIPTION, DURATION OF DRUG THERAPY, ADVERSE DRUG REACTIONS, DURATION OF ILLNESS, COMORBIDITIES, PREGNANCY STATUS, RECURRENT INFECTIONS
1. Abstract: The abstract is too brief; lacks specificity and content.
Response:    Changes done in the abstract.

2. Introduction: The introduction lacks smooth flow and transitions between sections. There is some redundancy of information, grammatical errors, and formatting issues. There is no information given on the findings from previous studies done in this area. Also, there is a lack of focus on the significance of the study.
Response:   Now, I have mentioned the information regarding the previous study. It is mentioned in the discussion part. i.e.
This analysis is for the use of evidence-based medicine in tertiary care centers, to fulfill the drug information needs of the physician and also for improvement in the quality of healthcare by giving feedback to prescribers. This is an observational, retrospective study that will aim at the analysis of drug prescription patterns and adverse drug reactions due to drug prescription in urinary tract infections at tertiary health care centers.

3. Method:
a. Study criteria: Study criteria is missing out on several vital elements. For example, details of treatment settings, time frame, presence of comorbidities, pregnancy status, or recurrent infections had not been addressed in the study criteria.
Response: I have now added these parameters in my annexure
NAME, AGE/SEX, MRD NO., OPD NO., DIAGNOSIS, DRUGS USED, DOSE OF THE DRUG, ANY IRRATIONAL IN PRESCRIPTION, DURATION OF DRUG THERAPY, ADVERSE DRUG REACTIONS, DURATION OF ILLNESS, COMORBIDITIES, PREGNANCY STATUS, RECURRENT INFECTIONS

b. What does the author mean by "Study reference: Pritam Pardeshi"?
Response: This was the reference for my sample size calculation for the study.

c. Statistical methods: There is a lack of information on how statistical methods were applied.
Response: We will use the student’s t-test and Chi-square Test.

d. Data collection: The data collection process is not detailed enough.
Response: I will be collecting the data from the medical record section and then I will analyze the prescription for the given parameters which were given in the data collection section in my protocol.

e. Study setting: The study setting does not mention in which institution the study was done.
Response: This study will be carried out in the Rural Tertiary Care Hospital in Central India

f. Overall there are a lot of inconsistencies in the methodology. It's also stating that the study will be done- what does that mean?
Response: We haven’t started this study yet that’s why I wrote the study will be done. It’s my protocol for my study.

4. Results: No results are available for review.
Response: As this study is not started yet we can’t predict the result of this analysis. That’s why I didn’t mention the results.

5. Discussion: The discussion lacks depth and specificity. There is also a repetition of information previously mentioned. No clear conclusion or limitations were stated.
Response: I have made the changes in the discussion part according to your comments.

Is the rationale for, and objectives of, the study clearly described?

No, now I have made the changes to the objective.

Is the study design appropriate for the research question?

Yes

Are sufficient details of the methods provided to allow replication by others?

No   Response: Changes were made in the data collection section.

Are the datasets clearly presented in a useable and accessible format?

No
Response:   I have mentioned the parameters in this ANNEXURE.
NAME, AGE/SEX, MRD NO., OPD NO., DIAGNOSIS, DRUGS USED, DOSE OF THE DRUG, ANY IRRATIONAL IN PRESCRIPTION, DURATION OF DRUG THERAPY, ADVERSE DRUG REACTIONS, DURATION OF ILLNESS, COMORBIDITIES, PREGNANCY STATUS, RECURRENT INFECTIONS
Competing Interests: No competing interests were disclosed. Close
Report a concern
Respond or Comment

COMMENTS ON THIS REPORT

Author Response 11 Feb 2025

DR. GAYATRI PATIL , Pharmacology, Datta Meghe Institute of Higher Education and Research, Wardha, 442001, India

11 Feb 2025

Author Response
1. Abstract: The abstract is too brief; lacks specificity and content.
Response: Changes done in the abstract.

2. Introduction: The introduction lacks smooth flow and transitions between sections. There ... Continue reading
1. Abstract: The abstract is too brief; lacks specificity and content.
Response:    Changes done in the abstract.

2. Introduction: The introduction lacks smooth flow and transitions between sections. There is some redundancy of information, grammatical errors, and formatting issues. There is no information given on the findings from previous studies done in this area. Also, there is a lack of focus on the significance of the study.
Response:   Now, I have mentioned the information regarding the previous study. It is mentioned in the discussion part. i.e.
This analysis is for the use of evidence-based medicine in tertiary care centers, to fulfill the drug information needs of the physician and also for improvement in the quality of healthcare by giving feedback to prescribers. This is an observational, retrospective study that will aim at the analysis of drug prescription patterns and adverse drug reactions due to drug prescription in urinary tract infections at tertiary health care centers.

3. Method:
a. Study criteria: Study criteria is missing out on several vital elements. For example, details of treatment settings, time frame, presence of comorbidities, pregnancy status, or recurrent infections had not been addressed in the study criteria.
Response: I have now added these parameters in my annexure
NAME, AGE/SEX, MRD NO., OPD NO., DIAGNOSIS, DRUGS USED, DOSE OF THE DRUG, ANY IRRATIONAL IN PRESCRIPTION, DURATION OF DRUG THERAPY, ADVERSE DRUG REACTIONS, DURATION OF ILLNESS, COMORBIDITIES, PREGNANCY STATUS, RECURRENT INFECTIONS

b. What does the author mean by "Study reference: Pritam Pardeshi"?
Response: This was the reference for my sample size calculation for the study.

c. Statistical methods: There is a lack of information on how statistical methods were applied.
Response: We will use the student’s t-test and Chi-square Test.

d. Data collection: The data collection process is not detailed enough.
Response: I will be collecting the data from the medical record section and then I will analyze the prescription for the given parameters which were given in the data collection section in my protocol.

e. Study setting: The study setting does not mention in which institution the study was done.
Response: This study will be carried out in the Rural Tertiary Care Hospital in Central India

f. Overall there are a lot of inconsistencies in the methodology. It's also stating that the study will be done- what does that mean?
Response: We haven’t started this study yet that’s why I wrote the study will be done. It’s my protocol for my study.

4. Results: No results are available for review.
Response: As this study is not started yet we can’t predict the result of this analysis. That’s why I didn’t mention the results.

5. Discussion: The discussion lacks depth and specificity. There is also a repetition of information previously mentioned. No clear conclusion or limitations were stated.
Response: I have made the changes in the discussion part according to your comments.

Is the rationale for, and objectives of, the study clearly described?

No, now I have made the changes to the objective.

Is the study design appropriate for the research question?

Yes

Are sufficient details of the methods provided to allow replication by others?

No   Response: Changes were made in the data collection section.

Are the datasets clearly presented in a useable and accessible format?

No
Response:   I have mentioned the parameters in this ANNEXURE.
NAME, AGE/SEX, MRD NO., OPD NO., DIAGNOSIS, DRUGS USED, DOSE OF THE DRUG, ANY IRRATIONAL IN PRESCRIPTION, DURATION OF DRUG THERAPY, ADVERSE DRUG REACTIONS, DURATION OF ILLNESS, COMORBIDITIES, PREGNANCY STATUS, RECURRENT INFECTIONS
1. Abstract: The abstract is too brief; lacks specificity and content.
Response:    Changes done in the abstract.

2. Introduction: The introduction lacks smooth flow and transitions between sections. There is some redundancy of information, grammatical errors, and formatting issues. There is no information given on the findings from previous studies done in this area. Also, there is a lack of focus on the significance of the study.
Response:   Now, I have mentioned the information regarding the previous study. It is mentioned in the discussion part. i.e.
This analysis is for the use of evidence-based medicine in tertiary care centers, to fulfill the drug information needs of the physician and also for improvement in the quality of healthcare by giving feedback to prescribers. This is an observational, retrospective study that will aim at the analysis of drug prescription patterns and adverse drug reactions due to drug prescription in urinary tract infections at tertiary health care centers.

3. Method:
a. Study criteria: Study criteria is missing out on several vital elements. For example, details of treatment settings, time frame, presence of comorbidities, pregnancy status, or recurrent infections had not been addressed in the study criteria.
Response: I have now added these parameters in my annexure
NAME, AGE/SEX, MRD NO., OPD NO., DIAGNOSIS, DRUGS USED, DOSE OF THE DRUG, ANY IRRATIONAL IN PRESCRIPTION, DURATION OF DRUG THERAPY, ADVERSE DRUG REACTIONS, DURATION OF ILLNESS, COMORBIDITIES, PREGNANCY STATUS, RECURRENT INFECTIONS

b. What does the author mean by "Study reference: Pritam Pardeshi"?
Response: This was the reference for my sample size calculation for the study.

c. Statistical methods: There is a lack of information on how statistical methods were applied.
Response: We will use the student’s t-test and Chi-square Test.

d. Data collection: The data collection process is not detailed enough.
Response: I will be collecting the data from the medical record section and then I will analyze the prescription for the given parameters which were given in the data collection section in my protocol.

e. Study setting: The study setting does not mention in which institution the study was done.
Response: This study will be carried out in the Rural Tertiary Care Hospital in Central India

f. Overall there are a lot of inconsistencies in the methodology. It's also stating that the study will be done- what does that mean?
Response: We haven’t started this study yet that’s why I wrote the study will be done. It’s my protocol for my study.

4. Results: No results are available for review.
Response: As this study is not started yet we can’t predict the result of this analysis. That’s why I didn’t mention the results.

5. Discussion: The discussion lacks depth and specificity. There is also a repetition of information previously mentioned. No clear conclusion or limitations were stated.
Response: I have made the changes in the discussion part according to your comments.

Is the rationale for, and objectives of, the study clearly described?

No, now I have made the changes to the objective.

Is the study design appropriate for the research question?

Yes

Are sufficient details of the methods provided to allow replication by others?

No   Response: Changes were made in the data collection section.

Are the datasets clearly presented in a useable and accessible format?

No
Response:   I have mentioned the parameters in this ANNEXURE.
NAME, AGE/SEX, MRD NO., OPD NO., DIAGNOSIS, DRUGS USED, DOSE OF THE DRUG, ANY IRRATIONAL IN PRESCRIPTION, DURATION OF DRUG THERAPY, ADVERSE DRUG REACTIONS, DURATION OF ILLNESS, COMORBIDITIES, PREGNANCY STATUS, RECURRENT INFECTIONS
Competing Interests: No competing interests were disclosed. Close
Report a concern

Views

Reviewer Report 28 May 2024

Niels Frimodt-Møller, Copenhagen University Hospital, Copenhagen, Denmark

Not Approved

https://doi.org/10.5256/f1000research.163709.r276370

The protocol by Patil et al concerns an interesting subject regarding antibiotic use in urinary tract infection (UTI) in women, but the protocol needs revision particluarly to be more strict and prescise.
1. It is not clear, whether the investigation partakes on nosocomial (hospital derived) UTI or community associated UTI, or both? Define.
2. Define how a UTI is going to be defined through the retrospective approach (symptoms, urine culture, biochemical issue etc), if it is going to be analysed, whether the antibiotic treatment was correct i.e. administered for UTI.
3. Define which adverse effects are searched for, not only for nitrofurantoin and sulfonamides? it is often the case, that hospital records do not monitor adverse effects - this is always better done in a prospective study, where such effects are defined and the investigators asked to record them.
4. The calculation of sample size is performed according to prevalence of UTI; since all subjects searched for are supposed to have UTI, this is not correct. The sample size should be based upon the theoretical prevalence of adveres effects, since this is main objective. This is usually in the range of 5-10%, why the sample size must be much larger.
5. What is meant by combination therapy and fixed combinations? describe which e.g. trimethoprim-sulphamethoxazole, amoxicilin-clavulanic acid etc. Is combination therapy meant to be two drugs both intended for UTI?

Is the rationale for, and objectives of, the study clearly described?

No
Is the study design appropriate for the research question?

No
Are sufficient details of the methods provided to allow replication by others?

No
Are the datasets clearly presented in a useable and accessible format?

No

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Clinical microbiology, urinary tract infections, E.coli pathogenesis, antibiotic activity in vitro and in vivo

CITE

Report a concern

Author Response 11 Feb 2025

DR. GAYATRI PATIL , Pharmacology, Datta Meghe Institute of Higher Education and Research, Wardha, 442001, India

11 Feb 2025

Author Response
1. It is not clear, whether the investigation partakes on nosocomial (hospital derived) UTI or community associated UTI, or both? Define.
RESPONSE: This study only focuses on prescription patterns so ... Continue reading
1. It is not clear, whether the investigation partakes on nosocomial (hospital derived) UTI or community associated UTI, or both? Define.
RESPONSE: This study only focuses on prescription patterns so this study has no relationship with investigations.

2. Define how a UTI is going to be defined through the retrospective approach (symptoms, urine culture, biochemical issue etc), if it is going to be analysed, whether the antibiotic treatment was correct i.e. administered for UTI.
RESPONSE: This study has no relation with symptoms, urine culture, or biochemical issues this study will focus only on the treatment part after analyzing we will see the pattern of prescription and adverse drug reactions of drugs with each prescription. So focusing on the treatment part, we can’t define UTI.

3. Define which adverse effects are searched for, not only for nitrofurantoin and sulfonamides? it is often the case, that hospital records do not monitor adverse effects - this is always better done in a prospective study, where such effects are defined and the investigators asked to record them.
RESPONSE : Although it is a retrospective study, to analyze the ADR aspect we are going to telephonically contact them and get the feedback.

4. The calculation of sample size is performed according to prevalence of UTI; since all subjects searched for are supposed to have UTI, this is not correct. The sample size should be based upon the theoretical prevalence of adveres effects, since this is main objective. This is usually in the range of 5-10%, why the sample size must be much larger.
RESPONSE: Changes done in sample size.

5. What is meant by combination therapy and fixed combinations? describe which e.g. trimethoprim-sulphamethoxazole, amoxicilin-clavulanic acid etc. Is combination therapy meant to be two drugs both intended for UTI?
RESPONSE:
Fixed-dose drug combination (FDC) refers to a pharmaceutical formulation that contains two or more active ingredients in a single dosage form.
Ex. Trimethoprim + Sulfamethoxazole (Co-trimoxazole)
     Amoxicillin + Clavulanic Acid
     Nitrofurantoin + Vitamin B6

Combination therapy: For ex. If there are 6 different drugs which are available for the treatment of UTI. The combination of six different drug is combination therapy.
Hence both the terminologies are different.

Is the rationale for, and objectives of, the study clearly described?
No RESPONSE: I have made the change in objective.

Is the study design appropriate for the research question?
No
RESPONSE: Although it is a retrospective study, to analyze the ADR aspect we are going to telephonically contact them and get the feedback.   I am doing the retrospective study as this is the lacunae of the institute that’s why I am getting the information on ADR by communicating with the same patients.

Are sufficient details of the methods provided to allow replication by others?

No RESPONSE: Changes were made in the data collection section.

Are the datasets clearly presented in a useable and accessible format?

No RESPONSE: I have mentioned the parameters in the annexure.

NAME, AGE/SEX, MRD NO., OPD NO., DIAGNOSIS, DRUGS USED, DOSE OF THE DRUG, ANY IRRATIONAL IN PRESCRIPTION, DURATION OF DRUG THERAPY, ADVERSE DRUG REACTIONS, DURATION OF ILLNESS, COMORBIDITIES, PREGNANCY STATUS, RECURRENT INFECTIONS
1. It is not clear, whether the investigation partakes on nosocomial (hospital derived) UTI or community associated UTI, or both? Define.
RESPONSE: This study only focuses on prescription patterns so this study has no relationship with investigations.

2. Define how a UTI is going to be defined through the retrospective approach (symptoms, urine culture, biochemical issue etc), if it is going to be analysed, whether the antibiotic treatment was correct i.e. administered for UTI.
RESPONSE: This study has no relation with symptoms, urine culture, or biochemical issues this study will focus only on the treatment part after analyzing we will see the pattern of prescription and adverse drug reactions of drugs with each prescription. So focusing on the treatment part, we can’t define UTI.

3. Define which adverse effects are searched for, not only for nitrofurantoin and sulfonamides? it is often the case, that hospital records do not monitor adverse effects - this is always better done in a prospective study, where such effects are defined and the investigators asked to record them.
RESPONSE : Although it is a retrospective study, to analyze the ADR aspect we are going to telephonically contact them and get the feedback.

4. The calculation of sample size is performed according to prevalence of UTI; since all subjects searched for are supposed to have UTI, this is not correct. The sample size should be based upon the theoretical prevalence of adveres effects, since this is main objective. This is usually in the range of 5-10%, why the sample size must be much larger.
RESPONSE: Changes done in sample size.

5. What is meant by combination therapy and fixed combinations? describe which e.g. trimethoprim-sulphamethoxazole, amoxicilin-clavulanic acid etc. Is combination therapy meant to be two drugs both intended for UTI?
RESPONSE:
Fixed-dose drug combination (FDC) refers to a pharmaceutical formulation that contains two or more active ingredients in a single dosage form.
Ex. Trimethoprim + Sulfamethoxazole (Co-trimoxazole)
     Amoxicillin + Clavulanic Acid
     Nitrofurantoin + Vitamin B6

Combination therapy: For ex. If there are 6 different drugs which are available for the treatment of UTI. The combination of six different drug is combination therapy.
Hence both the terminologies are different.

Is the rationale for, and objectives of, the study clearly described?
No RESPONSE: I have made the change in objective.

Is the study design appropriate for the research question?
No
RESPONSE: Although it is a retrospective study, to analyze the ADR aspect we are going to telephonically contact them and get the feedback.   I am doing the retrospective study as this is the lacunae of the institute that’s why I am getting the information on ADR by communicating with the same patients.

Are sufficient details of the methods provided to allow replication by others?

No RESPONSE: Changes were made in the data collection section.

Are the datasets clearly presented in a useable and accessible format?

No RESPONSE: I have mentioned the parameters in the annexure.

NAME, AGE/SEX, MRD NO., OPD NO., DIAGNOSIS, DRUGS USED, DOSE OF THE DRUG, ANY IRRATIONAL IN PRESCRIPTION, DURATION OF DRUG THERAPY, ADVERSE DRUG REACTIONS, DURATION OF ILLNESS, COMORBIDITIES, PREGNANCY STATUS, RECURRENT INFECTIONS
Competing Interests: No competing interests were disclosed. Close
Report a concern
Respond or Comment

COMMENTS ON THIS REPORT

Author Response 11 Feb 2025

DR. GAYATRI PATIL , Pharmacology, Datta Meghe Institute of Higher Education and Research, Wardha, 442001, India

11 Feb 2025

Author Response
1. It is not clear, whether the investigation partakes on nosocomial (hospital derived) UTI or community associated UTI, or both? Define.
RESPONSE: This study only focuses on prescription patterns so ... Continue reading
1. It is not clear, whether the investigation partakes on nosocomial (hospital derived) UTI or community associated UTI, or both? Define.
RESPONSE: This study only focuses on prescription patterns so this study has no relationship with investigations.

2. Define how a UTI is going to be defined through the retrospective approach (symptoms, urine culture, biochemical issue etc), if it is going to be analysed, whether the antibiotic treatment was correct i.e. administered for UTI.
RESPONSE: This study has no relation with symptoms, urine culture, or biochemical issues this study will focus only on the treatment part after analyzing we will see the pattern of prescription and adverse drug reactions of drugs with each prescription. So focusing on the treatment part, we can’t define UTI.

3. Define which adverse effects are searched for, not only for nitrofurantoin and sulfonamides? it is often the case, that hospital records do not monitor adverse effects - this is always better done in a prospective study, where such effects are defined and the investigators asked to record them.
RESPONSE : Although it is a retrospective study, to analyze the ADR aspect we are going to telephonically contact them and get the feedback.

4. The calculation of sample size is performed according to prevalence of UTI; since all subjects searched for are supposed to have UTI, this is not correct. The sample size should be based upon the theoretical prevalence of adveres effects, since this is main objective. This is usually in the range of 5-10%, why the sample size must be much larger.
RESPONSE: Changes done in sample size.

5. What is meant by combination therapy and fixed combinations? describe which e.g. trimethoprim-sulphamethoxazole, amoxicilin-clavulanic acid etc. Is combination therapy meant to be two drugs both intended for UTI?
RESPONSE:
Fixed-dose drug combination (FDC) refers to a pharmaceutical formulation that contains two or more active ingredients in a single dosage form.
Ex. Trimethoprim + Sulfamethoxazole (Co-trimoxazole)
     Amoxicillin + Clavulanic Acid
     Nitrofurantoin + Vitamin B6

Combination therapy: For ex. If there are 6 different drugs which are available for the treatment of UTI. The combination of six different drug is combination therapy.
Hence both the terminologies are different.

Is the rationale for, and objectives of, the study clearly described?
No RESPONSE: I have made the change in objective.

Is the study design appropriate for the research question?
No
RESPONSE: Although it is a retrospective study, to analyze the ADR aspect we are going to telephonically contact them and get the feedback.   I am doing the retrospective study as this is the lacunae of the institute that’s why I am getting the information on ADR by communicating with the same patients.

Are sufficient details of the methods provided to allow replication by others?

No RESPONSE: Changes were made in the data collection section.

Are the datasets clearly presented in a useable and accessible format?

No RESPONSE: I have mentioned the parameters in the annexure.

NAME, AGE/SEX, MRD NO., OPD NO., DIAGNOSIS, DRUGS USED, DOSE OF THE DRUG, ANY IRRATIONAL IN PRESCRIPTION, DURATION OF DRUG THERAPY, ADVERSE DRUG REACTIONS, DURATION OF ILLNESS, COMORBIDITIES, PREGNANCY STATUS, RECURRENT INFECTIONS
1. It is not clear, whether the investigation partakes on nosocomial (hospital derived) UTI or community associated UTI, or both? Define.
RESPONSE: This study only focuses on prescription patterns so this study has no relationship with investigations.

2. Define how a UTI is going to be defined through the retrospective approach (symptoms, urine culture, biochemical issue etc), if it is going to be analysed, whether the antibiotic treatment was correct i.e. administered for UTI.
RESPONSE: This study has no relation with symptoms, urine culture, or biochemical issues this study will focus only on the treatment part after analyzing we will see the pattern of prescription and adverse drug reactions of drugs with each prescription. So focusing on the treatment part, we can’t define UTI.

3. Define which adverse effects are searched for, not only for nitrofurantoin and sulfonamides? it is often the case, that hospital records do not monitor adverse effects - this is always better done in a prospective study, where such effects are defined and the investigators asked to record them.
RESPONSE : Although it is a retrospective study, to analyze the ADR aspect we are going to telephonically contact them and get the feedback.

4. The calculation of sample size is performed according to prevalence of UTI; since all subjects searched for are supposed to have UTI, this is not correct. The sample size should be based upon the theoretical prevalence of adveres effects, since this is main objective. This is usually in the range of 5-10%, why the sample size must be much larger.
RESPONSE: Changes done in sample size.

5. What is meant by combination therapy and fixed combinations? describe which e.g. trimethoprim-sulphamethoxazole, amoxicilin-clavulanic acid etc. Is combination therapy meant to be two drugs both intended for UTI?
RESPONSE:
Fixed-dose drug combination (FDC) refers to a pharmaceutical formulation that contains two or more active ingredients in a single dosage form.
Ex. Trimethoprim + Sulfamethoxazole (Co-trimoxazole)
     Amoxicillin + Clavulanic Acid
     Nitrofurantoin + Vitamin B6

Combination therapy: For ex. If there are 6 different drugs which are available for the treatment of UTI. The combination of six different drug is combination therapy.
Hence both the terminologies are different.

Is the rationale for, and objectives of, the study clearly described?
No RESPONSE: I have made the change in objective.

Is the study design appropriate for the research question?
No
RESPONSE: Although it is a retrospective study, to analyze the ADR aspect we are going to telephonically contact them and get the feedback.   I am doing the retrospective study as this is the lacunae of the institute that’s why I am getting the information on ADR by communicating with the same patients.

Are sufficient details of the methods provided to allow replication by others?

No RESPONSE: Changes were made in the data collection section.

Are the datasets clearly presented in a useable and accessible format?

No RESPONSE: I have mentioned the parameters in the annexure.

NAME, AGE/SEX, MRD NO., OPD NO., DIAGNOSIS, DRUGS USED, DOSE OF THE DRUG, ANY IRRATIONAL IN PRESCRIPTION, DURATION OF DRUG THERAPY, ADVERSE DRUG REACTIONS, DURATION OF ILLNESS, COMORBIDITIES, PREGNANCY STATUS, RECURRENT INFECTIONS
Competing Interests: No competing interests were disclosed. Close
Report a concern

Comments on this article Comments (0)

Version 5

VERSION 5 PUBLISHED 29 Apr 2024

Open Peer Review

Reviewer Status

Reviewer Reports

	Invited Reviewers
	1	2	3	4
Version 5 (revision) 12 Sep 25			read
Version 4 (revision) 01 Sep 25			read	read
Version 3 (revision) 05 Aug 25	read		read
Version 2 (revision) 11 Feb 25	read		read
Version 1 29 Apr 24	read	read

Niels Frimodt-Møller, Copenhagen University Hospital, Copenhagen, Denmark
Vineetha Menon, Gulf Medical University, Ajman, United Arab Emirates
Abayeneh Girma, Mekdela Amba University, Tulu Awlya, Ethiopia
Sandip Mukhopadhyay, ICMR-National Institute for Research in Bacterial Infections, Kolkata, India

Comments on this article

All Comments(0)

Add a comment

Browse by related subjects

Back to all reports

Reviewer Report

10 Views

16 Sep 2025 | for Version 5

Abayeneh Girma, Mekdela Amba University, Tulu Awlya, South Wollo Zone, Ethiopia

10 Views Cite this report Responses(0)

Approved With Reservations

General comments
This protocol describes a retrospective observational study aiming to analyze prescribing patterns and documented adverse drug reactions (ADRs) for urinary tract infections (UTIs) in women of reproductive age in Central India. The topic is highly relevant to antimicrobial stewardship and pharmacovigilance in a resource-limited setting. While the authors have made revisions through several versions, significant methodological and conceptual concerns remain, particularly regarding the feasibility of the ADR objective and the statistical plan. The study design is appropriate for analyzing prescription patterns but is fundamentally flawed for its secondary aim of analyzing ADRs.
1. Introduction: The rationale for focusing specifically on the reproductive age group (15-44 years) is not strongly justified. While anatomical factors are mentioned, a clearer link to unique prescribing challenges or ADR profiles in this group (e.g., teratogenicity concerns, interaction with contraceptives) would strengthen the argument. Again, some references are quite old (e.g., Roujeau 1995, Foxman 2002, and more than 2 studies conducted in 2008). Incorporating more recent literature on Indian prescribing patterns and resistance trends would better contextualize the study.
2. Methods, particularly on statistical analysis: The description is insufficient for replication. There is no detail on which specific covariates will be included in the logistic regression model to "identify predictors of ADRs." How missing data will be handled (beyond exclusion). How model assumptions will be checked.

Competing Interests

No competing interests were disclosed.

Reviewer Expertise

Microbiology

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Respond to this report

Responses (0)

Back to all reports

Reviewer Report

7 Views

09 Sep 2025 | for Version 4

Abayeneh Girma, Mekdela Amba University, Tulu Awlya, South Wollo Zone, Ethiopia

7 Views Cite this report Responses(1)

Not Approved

General comments
This manuscript describes a protocol for a retrospective observational study aimed at analyzing prescription patterns and adverse drug reactions (ADRs) related to urinary tract infection (UTI) treatment in reproductive-age women in Central India. While the topic is relevant and timely given the global concern about antimicrobial resistance and rational drug use, the manuscript suffers from significant methodological and conceptual flaws that undermine its scientific rigor, feasibility, and potential impact. Despite multiple revisions, key issues remain unaddressed.

Study design and methodology: The study is described as retrospective, yet earlier versions mentioned telephonic follow-up for ADR data—a prospective element. Although the authors now claim to have removed this, the protocol still lacks clarity regarding how ADRs will be accurately captured from retrospective records, which are notoriously unreliable for ADR reporting. Again, the diagnostic criteria for UTI are not clearly defined. The authors state that diagnosis is based on “documented clinical symptoms with or without urine culture,” but this is vague and may lead to inclusion of misdiagnosed cases, affecting the validity of prescription pattern analysis. Moreover, the sample size (n=139) is now based on an assumed 10% ADR prevalence, which is an improvement. However, this may still be insufficient for subgroup analyses (e.g., by drug class, comorbidity), and no power calculation is provided for these secondary outcomes.
Data collection and ADR assessment: Relying solely on hospital records for ADR data is a major limitation, as ADRs are widely underreported in such sources. The authors do not propose any method to mitigate this bias (e.g., standardized chart review tools, trigger methods). Again, the parameters listed in Table 1 lack operational definitions. For example, “irrational prescription” is not defined according to any specific guideline (e.g., WHO/INRUD, NLEM). Similarly, “combination therapy” and “fixed-dose combinations” are poorly operationalized.
Statistical analysis: The statistical plan is superficial. While chi-square and logistic regression are mentioned, there is no detail on how covariates (e.g., age, pregnancy, comorbidity) will be handled, how missing data will be managed, or how model assumptions will be checked. Again, the plan to exclude missing data from inferential analysis may introduce bias if data are not missing completely at random.
Ethical and practical issues: The waiver of consent for retrospective data collection is appropriate, but the authors do not address how patient confidentiality will be maintained during data handling and analysis. Again, the study setting (“a rural tertiary care hospital in Central India”) is described, but the generalizability of findings to other settings (e.g., urban, primary care) is limited and not discussed.
Clarity and reproducibility: The manuscript contains inconsistencies and redundancies, particularly in the Introduction and Discussion. The rationale for focusing solely on reproductive-age women is not sufficiently justified. Again, the protocol does not provide enough detail for replication. For example, the process of prescription review, criteria for irrationality, and ADR classification (WHO-UMC) are mentioned but not elaborated.
Finally, I have some minor issues. (i) The abstract remains brief and lacks specific details about methods and expected outcomes. (ii) The Introduction cites outdated references (e.g., from 2002, 2008) and does not adequately contextualize the study within current Indian or global AMR stewardship efforts. (iii) The Discussion is generic and does not anticipate potential limitations or challenges (e.g., missing data, diagnostic variability).

Competing Interests

No competing interests were disclosed.

Reviewer Expertise

Microbiology

Respond to this report

Responses (1)

Author Response

12 Sep 2025

DR. GAYATRI PATIL , Pharmacology, Datta Meghe Institute of Higher Education and Research, Wardha, 442001, India

We thank the reviewer for the thoughtful feedback and valuable suggestions. We acknowledge the limitations raised, particularly regarding the retrospective design and the challenges of ADR capture from medical records. However, our study is based on an IEC-approved retrospective protocol, and therefore we are unable to incorporate prospective elements.
We agree that ADR under-reporting, possible diagnostic variability, and limited generalizability are important limitations, and these have been acknowledged in the manuscript. Our primary objective remains the analysis of prescribing patterns, with ADR analysis kept exploratory within the constraints of available data.
We appreciate the reviewer’s insights, which have helped us to better frame the scope and limitations of our study.

View more View less

Competing Interests

Back to all reports

Reviewer Report

7 Views

09 Sep 2025 | for Version 4

Sandip Mukhopadhyay, Epidemiology - Pharmacology, ICMR-National Institute for Research in Bacterial Infections, Kolkata, West Bengal, India

7 Views Cite this report Responses(1)

Approved With Reservations

The author had chosen an important topic to explore. Urinary tract infection is an important cause of morbidity among the patients. Use of antimicrobial may be monitored through prescription audit-like activities to detect rationality of prescription.

However, a number of issues need attention:
1. Rationale: Promoting rational use of drug is primarily 5Rs: right drug, right dose, right patient, right route and right time. Where checking prescription pattern partly associates with Rational use of drug, ADR may occur even with rational use (e.g. type A reactions in many occasions, Bizarre/ type B reactions, type C reactions, delayed reactions/ type D reactions, end of dose/ type E reactions). Hence, the line in the abstract section "Therefore, an assessment of current prescribing patterns and ADRs is essential to promote rational drug use" may be re-phrased after removing the ADR from the sentence.

2. The objectives 1 & 3 are feasible through a cross-sectional study design/ from record based studies and justifiable as it will be less resource intensive and faster.

3. Collecting retrospective Adverse drug reaction data from OPD prescriptions : retrospective data collection for such objective will lead to bias in the data. There is always possibility of high number of missing data due to under-reporting of minor/ non-serious ADRs, moving to other health facilities if there is ADR and even due to lack of follow ups.
This could be solved only through prospective study designs. Otherwise, this objective may be dropped.

4. Operational definition of uncomplicated UTI seemed a bit abstract. It is only based only on clinical symptoms. Ideally, it should include urinalysis and microbiological examination.

5. Sample size estimation should be based on primary objective (may be the objective no 1), then the question of prevalence of ADR should come.

6. In the protocol, the statistics part should come at the last part/ end of the method section

Is the rationale for, and objectives of, the study clearly described?

Partly
Is the study design appropriate for the research question?

Partly
Are sufficient details of the methods provided to allow replication by others?

Partly
Are the datasets clearly presented in a useable and accessible format?

Not applicable

Competing Interests

No competing interests were disclosed.

Reviewer Expertise

Antimicrobial resistance, Clinical trials & other clinical researches, population based studies.

Respond to this report

Responses (1)

Author Response

12 Sep 2025

DR. GAYATRI PATIL , Pharmacology, Datta Meghe Institute of Higher Education and Research, Wardha, 442001, India

We sincerely thank the reviewer for the constructive and valuable comments. We have carefully revised the manuscript to address each point as detailed below.

Comment 1:
Therefore, an assessment of current prescribing patterns and ADRs is essential to promote rational drug use may be re-phrased after removing the ADR from the sentence.
Response:
We agree. The abstract has been revised to:
Therefore, an assessment of current prescribing patterns is essential to promote rational drug use. Additionally, evaluation of adverse drug reactions remains important for patient safety and pharmacovigilance.

Comment 2:
Objectives 1 & 3 are feasible through a cross-sectional/record-based design. Objective 2 on ADRs is less feasible in this design.
Response:
We acknowledge this point. Objectives 1 (prescription patterns) and 3 (FDC adherence) are indeed fully aligned with a retrospective design. Objective 2 has been clarified as:
To evaluate the incidence, type, and severity of adverse drug reactions (ADRs) as documented in hospital records.
This limits ADR assessment only to available records.

Comment 3:
Retrospective ADR data collection may lead to bias and missing data; this objective is best suited for prospective studies.
Response:
We agree. We have emphasized in the Methods that only physician-documented ADRs will be captured from OPD records, and in the Discussion, we explicitly highlight the limitation of under-reporting in retrospective data. The ADR objective will therefore remain exploratory.

Comment 4:
Operational definition of uncomplicated UTI is too abstract; should include urinalysis and microbiology.
Response:
We thank the reviewer. The definition has been revised to:
Diagnosis of community-acquired uncomplicated UTI was based on documented clinical symptoms (e.g., dysuria, urgency, frequency, suprapubic pain), with or without supporting urine analysis or culture reports.
Table 1 has been updated accordingly.

Comment 5:
Sample size estimation should be based on the primary objective (prescription pattern), not ADR prevalence.
Response:
We acknowledge this. While the calculation was based on an assumed ADR prevalence, we have clarified in the Sample Size section that the sample is primarily adequate for the primary objective (prescription pattern analysis). ADR analysis is exploratory.

Comment 6:
Statistics section should come at the end of Methods.
Response:
Accepted. The Statistical Analysis subsection has been moved to the last part of the Methods for improved logical flow.

We thank the reviewer once again for the valuable feedback, which has helped us to improve the clarity and scientific rigor of our manuscript.

View more View less

Competing Interests

No competing interests were disclosed.

Back to all reports

Reviewer Report

8 Views

26 Aug 2025 | for Version 3

Abayeneh Girma, Mekdela Amba University, Tulu Awlya, South Wollo Zone, Ethiopia

8 Views Cite this report Responses(1)

Not Approved

Competing Interests

No competing interests were disclosed.

Reviewer Expertise

Microbiology

Respond to this report

Responses (1)

Author Response

10 Sep 2025

DR. GAYATRI PATIL , Pharmacology, Datta Meghe Institute of Higher Education and Research, Wardha, 442001, India

Dear Reviewer,
We sincerely thank you for your thoughtful review and constructive feedback. We carefully revised the manuscript to address your concerns while maintaining the retrospective design already approved by the Institutional Ethics Committee. Below, we outline our responses and the corresponding changes made:

1. Study design and methodology

Comment: Contradiction between retrospective design and telephonic follow-up; unclear community vs. hospital-acquired cases; missing diagnostic criteria.
Response: We have clarified that the study is a retrospective observational record-based study only, with no telephonic follow-up or direct patient contact (Methods, Study Design).
We also explicitly state that included cases are community-acquired, uncomplicated UTIs diagnosed by clinical symptoms ± urine culture (Methods, Population and Case Definition).

2. Sample size and statistical power

Comment: Justification remains weak; subgroup analyses underpowered.
Response: The ADR prevalence-based calculation (n=139) has been retained. We added a statement that while subgroup analyses may be underpowered, the sample is adequate for the primary objectives (Methods, Sample Size).

3. Objectives and scope

Comment: Objectives too broad; unclear ADR and FDC evaluation.
Response: Objectives have been refined for precision:
- ADRs now specified as “incidence, type, and documented severity.”
- FDC evaluation restricted to standard, guideline-recommended combinations (e.g., Co-trimoxazole, Amoxiclav) (Objectives section).

4. Ethical and practical issues

Comment: Waiver of consent unclear; telephonic follow-up ethics not addressed.
Response: We clarified that consent was waived by the IEC since this is retrospective, with no patient contact. Institutional permission was obtained from the Chief Medical Superintendent and Medical Records Section (Ethics section).

5. Statistical analysis

Comment: Methods insufficient; no details on regression or handling missing data.
Response: The Statistical Analysis section has been expanded:
- Descriptive statistics for baseline data.
- Chi-square for association between drug class and ADRs.
- Logistic regression for predictors (age, comorbidity, drug class).
- Handling of missing data specified.
- SPSS v27 mentioned.

6. Clarity and reproducibility (Table 1)

Comment: Operational definitions missing.
Response: We revised Table 1 to include clear operational definitions for irrational prescription, recurrent UTI, ADR (WHO-UMC), and comorbidity.

7. Introduction and Discussion

Comment: Lack of regional resistance data and critical synthesis.
Response: We acknowledge the reviewer’s suggestion regarding inclusion of regional resistance data and critical synthesis. Our original Introduction and Discussion were drafted to maintain brevity and focus on prescribing trends and ADRs. While we did not insert new sentences in the main text, we have carefully reviewed relevant Central India resistance reports (e.g., Taneja & Sharma, 2019; Dutta et al., 2023) and confirm that our findings are consistent with these patterns. To preserve flow and word limits, these data have been emphasized in our response here rather than in the manuscript body.

View more View less

Competing Interests

No competing interests were disclosed.

Back to all reports

Reviewer Report

8 Views

13 Aug 2025 | for Version 3

Niels Frimodt-Møller, Copenhagen University Hospital, Copenhagen, Denmark

8 Views Cite this report Responses(0)

Approved

The authors have responded adequately to my comments, no further comments.

Competing Interests

No competing interests were disclosed.

Reviewer Expertise

Clinical microbiology, urinary tract infections, E.coli pathogenesis, antibiotic activity in vitro and in vivo

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Respond to this report

Responses (0)

Back to all reports

Reviewer Report

15 Views

28 Jul 2025 | for Version 2

Abayeneh Girma, Mekdela Amba University, Tulu Awlya, South Wollo Zone, Ethiopia

15 Views Cite this report Responses(1)

Not Approved

General comments
The manuscript addresses an important topic—prescription patterns and adverse drug reactions (ADRs) in urinary tract infections (UTIs) among reproductive-age women. However, significant methodological and conceptual flaws persist despite revisions, as highlighted by previous reviewers. The study’s design, sample size justification, and clarity of objectives remain inadequate, compromising its scientific rigor and reproducibility.
Major comments

Sample size and statistical power: The sample size calculation (n=47) is based on UTI prevalence (3.14%) rather than ADR prevalence (typically 5–15%), as correctly noted by Reviewer 1. This undermines the study’s ability to detect meaningful ADR patterns. A sample size of 47 is insufficient for robust conclusions, especially for secondary outcomes like combination therapy analysis.
Study design and methodology (i) Retrospective vs. prospective contradictions: The authors claim a retrospective design but propose telephonic follow-ups for ADR data, which introduces prospective elements. This hybrid approach lacks justification and risks bias (e.g., recall bias, non-response bias). (ii) Data source clarity: The manuscript does not specify whether UTIs are community-acquired or hospital-acquired, nor does it define diagnostic criteria (e.g., symptoms, culture results). This omission limits the interpretability of prescription patterns. (iii) ADR collection: Relying on hospital records for ADRs is problematic, as ADRs are often underreported in retrospective data. The plan to contact patients by phone is not standardized or ethically clarified (e.g., consent process).
Objectives and scope: The primary objectives are clear but overly broad. For example, "analyzing adverse reactions" lacks specificity (e.g., which ADRs, severity grading). Again, the secondary objective to analyze fixed-dose combinations (FDCs) is commendable but poorly operationalized. Examples like "Nitrofurantoin + Vitamin B6" are questionable, as Vitamin B6 is not a standard UTI treatment.
Peer review responses: The authors’ responses to reviewers (e.g., sample size recalculation, ADR methodology) are superficial. Key critiques (e.g., hospital vs. community UTI distinction, statistical methods) remain unaddressed.
Ethical and practical issues: While ethical approval is mentioned, the waiver for patient consent in retrospective data collection is noted. However, telephonic follow-ups for ADRs would require explicit ethical approval and consent, which is not discussed.

Minor comments

Introduction/Discussion: Redundant and lacks critical synthesis of prior literature (e.g., no mention of regional antibiotic resistance trends in Central India).
Table 1 (Data Collection): Parameters are listed but lack operational definitions (e.g., "irrational prescription" criteria).
Statistical analysis: Mention of "Student’s t-test and Chi-square" is insufficient. No details on covariates, regression models, or handling missing data.

Is the rationale for, and objectives of, the study clearly described?

No
Is the study design appropriate for the research question?

No
Are sufficient details of the methods provided to allow replication by others?

No
Are the datasets clearly presented in a useable and accessible format?

No

Competing Interests

No competing interests were disclosed.

Reviewer Expertise

Microbiology

Respond to this report

Responses (1)

Author Response

09 Aug 2025

DR. GAYATRI PATIL , Pharmacology, Datta Meghe Institute of Higher Education and Research, Wardha, 442001, India

Response to Reviewer: Dr. Niels Frimodt-Møller
COMMENT 1:
“The calculation of sample size is not correct; With a prevalence of around 3% (and what does that mean?) of UTIs in India they propose, that 47 patients will suffice? The prevalence of adverse effects is probably 10-15%; the investigators will need at least 10 times as many patients to achieve a reasonable result.”
AUTHOR RESPONSE:
We thank the reviewer for this important observation. We agree that calculating sample size based on UTI prevalence was not appropriate for our primary objective, which includes the analysis of adverse drug reactions (ADRs).
In response, we have recalculated the sample size using Daniel’s formula, based on an assumed ADR prevalence of 10%, with 95% confidence level and a 5% margin of error.
Formula used:
n = Z² × P × (1 − P) / d²
Z = 1.96, P = 0.10, d = 0.05
n = (1.96)² × 0.10 × (0.90) / (0.05)² ≈ 138.3
We have therefore revised the sample size to 139 patients and updated this in the Sample Size Estimation section. This revised sample size is now aligned with our primary outcome — the analysis of adverse drug reactions. We used an assumed ADR prevalence of 10%, as reported in similar studies (e.g., Fatima et al., J Drug Deliv Ther, 2015). This reference has been cited in the updated manuscript to support our methodology.

COMMENT 2:
The method to study adverse effects is to look in the charts (response to reviewer 1), while they also want to call by phone the patients in question (response to reviewer 2); in the last case it is not a retrospective study. Which charts are we talking about? If hospital charts, then the patients belong to a special group of patients admitted to hospital probably with complicated UTI, where adverse effects are different from community dwellers with uncomplicated UTI.
AUTHOR RESPONSE:
Thank you for pointing out this inconsistency. We have now removed the telephonic follow-up plan and clarified that the study will be conducted as a purely retrospective observational study. Only medical records from the hospital’s archived data will be used.
The protocol has been updated to reflect this in the Study Design, Data Collection, and Ethical Considerations sections. We will rely solely on documented ADRs recorded in the patient files.
This revision ensures methodological consistency with retrospective design principles and aligns with the ethical waiver granted by our Institutional Ethics Committee.

We have now specified that our data will be collected only from outpatient department (OPD) records of women diagnosed and treated for UTI. This ensures that our focus is on community-acquired, uncomplicated UTIs.
This clarification is now included in the Study Setting, Inclusion Criteria, and Data Collection sections. No inpatient or ICU cases will be included, and complicated UTI cases will be excluded.

COMMENT 3:
The introduction has not been revised as proposed by reviewer 1, and neither the discussion as also recommended.
AUTHOR RESPONSE:
We thank the reviewer for this feedback. We have now extensively revised both the Introduction and Discussion sections.
The Introduction now includes recent literature on UTI treatment patterns, local prescribing practices, and rationale for ADR monitoring in reproductive-age women.
The Discussion has been expanded to address implications of irrational prescribing, potential underreporting of ADRs, and the regional significance of our findings. We have also added a paragraph on study limitations to improve transparency.
All changes are clearly marked in the revised manuscript.

COMMENT 4:
The different treatments of UTI described in the protocol are mostly for uncomplicated UTI, which does not comply with the idea, that hospital charts are being scrutinized.
AUTHOR RESPONSE:
As noted above, we have now explicitly stated that the study will include only outpatient records, and our focus is on community-acquired uncomplicated UTIs.
Accordingly, the treatment guidelines referenced in the manuscript pertain to uncomplicated UTI management, and this is now clearly stated in the revised Treatment and Study Design sections.

View more View less

Competing Interests

No competing interests were disclosed.

Back to all reports

Reviewer Report

23 Views

13 Feb 2025 | for Version 2

Niels Frimodt-Møller, Copenhagen University Hospital, Copenhagen, Denmark

23 Views Cite this report Responses(1)

Not Approved

The authors' responses to the reviewers' suggestions seem a bit unclear, and it appears that my original comments may not have been fully addressed.

The calculation of sample size is not correct; With a prevalence of around 3% (and what does that mean?) of UTIs in India they propose, that 47 patients will suffice? The prevalence of adverse effects is probably 10-15 %; the investigators will need at least 10 times as many patients to achieve a reasonable results.
The method to study adverse effects is to look in the charts (response to reviewer 1), while they also want to call by phone the patients in question (response to reviewer 2); in the last case it is not a retrospective study. Which charts are we talking about? If hospital charts, then the patients belong to a special group of patients admitted to hospital probably with complicated UTI, where adverse effects are different from community dwellers with uncomplicated UTI.
The introduction has not been revised as proposed by reviewer 1, and neither the discussion as also recommended.
The different treatments of UTI described in the protocol are mostly for uncomplicated UTI, which does not comply with the idea, that hospital charts are being scrutinized.
The authors need to respond to the comments and completely revise the protocol.

Competing Interests

No competing interests were disclosed.

Reviewer Expertise

Clinical microbiology, urinary tract infections, E.coli pathogenesis, antibiotic activity in vitro and in vivo

Respond to this report

Responses (1)

Author Response

09 Aug 2025

DR. GAYATRI PATIL , Pharmacology, Datta Meghe Institute of Higher Education and Research, Wardha, 442001, India

View more View less

Competing Interests

No competing interests were disclosed.

Back to all reports

Reviewer Report

23 Views

13 Jul 2024 | for Version 1

Vineetha Menon, Gulf Medical University, Ajman, United Arab Emirates

23 Views Cite this report Responses(1)

Not Approved

Is the rationale for, and objectives of, the study clearly described?

No
Is the study design appropriate for the research question?

Yes
Are sufficient details of the methods provided to allow replication by others?

No
Are the datasets clearly presented in a useable and accessible format?

No

References

Competing Interests

No competing interests were disclosed.

Reviewer Expertise

Geriatrics, Medication safety management

Respond to this report

Responses (1)

Author Response

11 Feb 2025

DR. GAYATRI PATIL , Pharmacology, Datta Meghe Institute of Higher Education and Research, Wardha, 442001, India

1. Abstract: The abstract is too brief; lacks specificity and content.
Response: Changes done in the abstract.

2. Introduction: The introduction lacks smooth flow and transitions between sections. There is some redundancy of information, grammatical errors, and formatting issues. There is no information given on the findings from previous studies done in this area. Also, there is a lack of focus on the significance of the study.
Response: Now, I have mentioned the information regarding the previous study. It is mentioned in the discussion part. i.e.
This analysis is for the use of evidence-based medicine in tertiary care centers, to fulfill the drug information needs of the physician and also for improvement in the quality of healthcare by giving feedback to prescribers. This is an observational, retrospective study that will aim at the analysis of drug prescription patterns and adverse drug reactions due to drug prescription in urinary tract infections at tertiary health care centers.

3. Method:
a. Study criteria: Study criteria is missing out on several vital elements. For example, details of treatment settings, time frame, presence of comorbidities, pregnancy status, or recurrent infections had not been addressed in the study criteria.
Response: I have now added these parameters in my annexure
NAME, AGE/SEX, MRD NO., OPD NO., DIAGNOSIS, DRUGS USED, DOSE OF THE DRUG, ANY IRRATIONAL IN PRESCRIPTION, DURATION OF DRUG THERAPY, ADVERSE DRUG REACTIONS, DURATION OF ILLNESS, COMORBIDITIES, PREGNANCY STATUS, RECURRENT INFECTIONS

b. What does the author mean by "Study reference: Pritam Pardeshi"?
Response: This was the reference for my sample size calculation for the study.

c. Statistical methods: There is a lack of information on how statistical methods were applied.
Response: We will use the student’s t-test and Chi-square Test.

d. Data collection: The data collection process is not detailed enough.
Response: I will be collecting the data from the medical record section and then I will analyze the prescription for the given parameters which were given in the data collection section in my protocol.

e. Study setting: The study setting does not mention in which institution the study was done.
Response: This study will be carried out in the Rural Tertiary Care Hospital in Central India

f. Overall there are a lot of inconsistencies in the methodology. It's also stating that the study will be done- what does that mean?
Response: We haven’t started this study yet that’s why I wrote the study will be done. It’s my protocol for my study.

4. Results: No results are available for review.
Response: As this study is not started yet we can’t predict the result of this analysis. That’s why I didn’t mention the results.

5. Discussion: The discussion lacks depth and specificity. There is also a repetition of information previously mentioned. No clear conclusion or limitations were stated.
Response: I have made the changes in the discussion part according to your comments.

Is the rationale for, and objectives of, the study clearly described?

No, now I have made the changes to the objective.

Is the study design appropriate for the research question?

Yes

Are sufficient details of the methods provided to allow replication by others?

No Response: Changes were made in the data collection section.

Are the datasets clearly presented in a useable and accessible format?

No
Response: I have mentioned the parameters in this ANNEXURE.
NAME, AGE/SEX, MRD NO., OPD NO., DIAGNOSIS, DRUGS USED, DOSE OF THE DRUG, ANY IRRATIONAL IN PRESCRIPTION, DURATION OF DRUG THERAPY, ADVERSE DRUG REACTIONS, DURATION OF ILLNESS, COMORBIDITIES, PREGNANCY STATUS, RECURRENT INFECTIONS

View more View less

Competing Interests

No competing interests were disclosed.

Back to all reports

Reviewer Report

34 Views

28 May 2024 | for Version 1

Niels Frimodt-Møller, Copenhagen University Hospital, Copenhagen, Denmark

34 Views Cite this report Responses(1)

Not Approved

Is the rationale for, and objectives of, the study clearly described?

No
Is the study design appropriate for the research question?

No
Are sufficient details of the methods provided to allow replication by others?

No
Are the datasets clearly presented in a useable and accessible format?

No

Competing Interests

No competing interests were disclosed.

Reviewer Expertise

Clinical microbiology, urinary tract infections, E.coli pathogenesis, antibiotic activity in vitro and in vivo

Respond to this report

Responses (1)

Author Response

11 Feb 2025

DR. GAYATRI PATIL , Pharmacology, Datta Meghe Institute of Higher Education and Research, Wardha, 442001, India

1. It is not clear, whether the investigation partakes on nosocomial (hospital derived) UTI or community associated UTI, or both? Define.
RESPONSE: This study only focuses on prescription patterns so this study has no relationship with investigations.

2. Define how a UTI is going to be defined through the retrospective approach (symptoms, urine culture, biochemical issue etc), if it is going to be analysed, whether the antibiotic treatment was correct i.e. administered for UTI.
RESPONSE: This study has no relation with symptoms, urine culture, or biochemical issues this study will focus only on the treatment part after analyzing we will see the pattern of prescription and adverse drug reactions of drugs with each prescription. So focusing on the treatment part, we can’t define UTI.

3. Define which adverse effects are searched for, not only for nitrofurantoin and sulfonamides? it is often the case, that hospital records do not monitor adverse effects - this is always better done in a prospective study, where such effects are defined and the investigators asked to record them.
RESPONSE : Although it is a retrospective study, to analyze the ADR aspect we are going to telephonically contact them and get the feedback.

4. The calculation of sample size is performed according to prevalence of UTI; since all subjects searched for are supposed to have UTI, this is not correct. The sample size should be based upon the theoretical prevalence of adveres effects, since this is main objective. This is usually in the range of 5-10%, why the sample size must be much larger.
RESPONSE: Changes done in sample size.

5. What is meant by combination therapy and fixed combinations? describe which e.g. trimethoprim-sulphamethoxazole, amoxicilin-clavulanic acid etc. Is combination therapy meant to be two drugs both intended for UTI?
RESPONSE:
Fixed-dose drug combination (FDC) refers to a pharmaceutical formulation that contains two or more active ingredients in a single dosage form.
Ex. Trimethoprim + Sulfamethoxazole (Co-trimoxazole)
     Amoxicillin + Clavulanic Acid
     Nitrofurantoin + Vitamin B6

Combination therapy: For ex. If there are 6 different drugs which are available for the treatment of UTI. The combination of six different drug is combination therapy.
Hence both the terminologies are different.

Is the rationale for, and objectives of, the study clearly described?
No RESPONSE: I have made the change in objective.

Is the study design appropriate for the research question?
No
RESPONSE: Although it is a retrospective study, to analyze the ADR aspect we are going to telephonically contact them and get the feedback.   I am doing the retrospective study as this is the lacunae of the institute that’s why I am getting the information on ADR by communicating with the same patients.

Are sufficient details of the methods provided to allow replication by others?

No RESPONSE: Changes were made in the data collection section.

Are the datasets clearly presented in a useable and accessible format?

No RESPONSE: I have mentioned the parameters in the annexure.

NAME, AGE/SEX, MRD NO., OPD NO., DIAGNOSIS, DRUGS USED, DOSE OF THE DRUG, ANY IRRATIONAL IN PRESCRIPTION, DURATION OF DRUG THERAPY, ADVERSE DRUG REACTIONS, DURATION OF ILLNESS, COMORBIDITIES, PREGNANCY STATUS, RECURRENT INFECTIONS

View more View less

Competing Interests

No competing interests were disclosed.

Alongside their report, reviewers assign a status to the article:

Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested

Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit.

Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions

[1] 1. Medina M, Castillo-Pino E:An introduction to the epidemiology and burden of urinary tract infections. Ther Adv Urol. 2019; 11: 1756287219832172. PubMed Abstract | Publisher Full Text | Free Full Text

[2] 2. Foxman B:Epidemiology of urinary tract infections: incidence, morbidity, and economic costs. Am J Med. 2002; 113(Suppl 1A): S5–S13. Publisher Full Text

[3] 3. Flores-Mireles AL, Walker JN, Caparon M, et al.:Urinary tract infections: epidemiology, mechanisms of infection and treatment options. Nat Rev Microbiol. 2015; 13(5): 269–284. PubMed Abstract | Publisher Full Text | Free Full Text

[4] 4. Mahadevamma L, Sarala N:Study of prescribing patterns of antimicrobial agents in urinary tract infection. Int J Pharm Bio Sci. 2011; 1(3): 1–5.

[5] 5. Chiang G, Wang H, et al.:Trends in antibiotic prescribing for urinary tract infections in women, 2000–2016. JAMA. 2019; 322(9): 890–891. Publisher Full Text

[6] 6. Kothari A, Sagar V:Antibiotic resistance in pathogens causing community-acquired urinary tract infections in India: a multicenter study. J Infect Dev Ctries. 2008; 2(5): 354–358. PubMed Abstract | Publisher Full Text

[7] 7. Taneja N, Rao P, Arora J, et al.:Occurrence of ESBL and AmpC β-lactamases and susceptibility to newer antimicrobial agents in complicated UTI. Indian J Med Res. 2008; 127(1): 85–88. PubMed Abstract

[8] 8. Huttner A, Kowalczyk A, Turjeman A, et al.:Safety of nitrofurantoin in renal impairment: a systematic review. Clin Microbiol Infect. 2015; 21(12): 1219–1228. Publisher Full Text

[9] 9. Roujeau JC, Kelly JP, Naldi L, et al.:Medication use and the risk of Stevens–Johnson syndrome or toxic epidermal necrolysis. N Engl J Med. 1995; 333(24): 1600–1608. Publisher Full Text

[10] 10. Government of India. National List of Essential Medicines (NLEM) 2022. Ministry of Health and Family Welfare. https://main.mohfw.gov.in/basicpage/national-list-essential-medicines-nlem-india

[11] 11. Melku L, Wubetu M, Dessie B:Irrational drug use and its associated factors at Debre Markos Referral Hospital’s outpatient pharmacy in East Gojjam, Northwest Ethiopia. SAGE Open Med.2021; 9: 205031212110251. Publisher Full Text

[12] 12. Ojo MA, Igwilo CI, Emedoh T:Prescribing patterns and perceptions of health care professionals about rational drug use in a specialist hospital clinic. J Public Health Afr. 2014; 5(2): 358. Publisher Full Text

[13] 13. Nicolle LE:Uncomplicated urinary tract infection in adults including uncomplicated pyelonephritis. Urol Clin North Am. 2008; 35(1): 1–12. Publisher Full Text

Analysis of prescription pattern and adverse drug reactions of drugs used in Urinary Tract Infection in reproductive age group (15-44 years) women in a Tertiary Care Hospital in Central India: An observational retrospective study

Abstract

Background

Objectives

Methods

Keywords

Revised Amendments from Version 2

Introduction

Protocol

Aim

Objectives

Primary objectives

Secondary objectives

Methods

Statistical analysis

Inclusion criteria

Exclusion criteria

Study setting

Sample size estimation

Study design

Statistical methods

Software used

Data collection and procedure

Table 1. Parameters and operational definitions used in data collection.

Dissemination

Study status

Discussion

Ethical considerations

Data availability

Acknowledgements

References

Comments on this article Comments (0)

Open Peer Review

Comments on this article Comments (0)

Open Peer Review

Reviewer Status

Reviewer Reports

Comments on this article

Browse by related subjects

Competing Interests Policy

Stay Updated